Publications

You may also search for publications by trial by visiting our trial index.

For information on the entire TIMI Study Group publication library, contact our Academic Coordinator

Remote Cardiovascular Hypertension Program Enhanced Blood Pressure Control During the COVID-19 Pandemic. Lee SG, Blood AJ, Cannon CP, Gordon WJ, Nichols H, Zelle D, Scirica BM, Fisher NDL. J Am Heart Assoc. 2023 Mar 13:e027296. doi: 10.1161/JAHA.122.027296.

Race, ethnicity, sex, and socioeconomic disparities in anticoagulation for atrial fibrillation: A narrative review of contemporary literature. Daly DJ, Essien UR, Del Carmen MG, Scirica B, Berman AN, Searl Como J, Wasfy JH. J Natl Med Assoc. 2023 Mar 5:S0027-9684(23)00034-2. doi: 10.1016/j.jnma.2023.02.008.

Outcomes In High-risk Pulmonary Embolism Patients Undergoing FlowTriever Mechanical Thrombectomy: The FLAME Study in Perspective. Morrow DA, Bergmark BA. Eur Heart J Acute Cardiovasc Care. 2023 Mar 7:zuad022. doi: 10.1093/ehjacc/zuad022.

Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. Butt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Vardeny O, O’Meara E, Saraiva JFK, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. JACC Heart Fail. 2022 Dec 21:S2213-1779(22)00704-1. doi: 10.1016/j.jchf.2022.11.014.

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, Murphy SA, Zelniker TA, Fredriksson M, Johansson PA, Leiter LA, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Cahn A, Langkilde AM, Sabatine MS, Mosenzon O. Lancet Diabetes Endocrinol. 2023 Mar 3:S2213-8587(23)00009-8. doi: 10.1016/S2213-8587(23)00009-8.

Sex-Related Differences in Patients Characteristics, Risk Factors, and Symptomatology in Older Adults with Pulmonary Embolism: Findings from the SERIOUS-PE Study. Bikdeli B, Muriel A, Wang Y, Piazza G, Khairani CD, Rosovsky RP, Mehdipoor G, O’Donoghue ML, Madridano O, Lopez-Saez JB, Mellado M, Brasero AMD, Grandone E, Spagnolo PA, Lu Y, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Gerhard-Herman M, Goldhaber SZ, Bates SM, Jimenez D, Krumholz HM, Monreal M; RIETE Investigators. Semin Thromb Hemost. 2023 Mar 3. doi: 10.1055/s-0043-1764231.

Critical Appraisal of the Negative Predictive Performance of the European Society of Cardiology 0/1-Hour Algorithm for Evaluating Patients With Chest Pain in the US. Karády J, Morrow DA. JAMA Cardiol. 2023 Mar 1. doi: 10.1001/jamacardio.2023.0043.

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. Zelniker TA, Wiviott SD, Mosenzon O, Goodrich EL, Jarolim P, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Averkov O, Budaj A, Parkhomenko A, Ray KK, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Morrow DA. JAMA Cardiol. 2023 Mar 1:e230019. doi: 10.1001/jamacardio.2023.0019.

Percutaneous Treatment of High-Risk Pulmonary Embolism: Bridging the Evidence Gap. Almarzooq ZI, Bergmark BA. Eur Heart J Acute Cardiovasc Care. 2023 Feb 23:zuad016. doi: 10.1093/ehjacc/zuad016.

A miRNA-CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. Cheng HS, Zhuang R, Pérez-Cremades D, Chen J, Jamaiyar A, Wu W, Sausen G, Tzani A, Plutzky J, Henao-Mejia J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. JCI Insight. 2023 Feb 23:e163360. doi: 10.1172/jci.insight.163360.

Privacy-aware multi-institutional time-to-event studies. Späth J, Matschinske J, Kamanu FK, Murphy SA, Zolotareva O, Bakhtiari M, Antman EM, Loscalzo J, Brauneck A, Schmalhorst L, Buchholtz G, Baumbach J. PLOS Digit Health. 2022 Sep 6;1(9):e0000101. doi: 10.1371/journal.pdig.0000101. eCollection 2022 Sep.

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. Butt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. JAMA Cardiol. 2023 Feb 22:e225608. doi: 10.1001/jamacardio.2022.5608.

Pulling Out All the Stops: A Case of Progressive Dyspnea. Ostrominski JW, Bhatt DL, Scirica BM. Circulation. 2023 Feb 21;147(8):688-693. doi: 10.1161/CIRCULATIONAHA.122.062753. Epub 2023 Feb 20.

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/valsartan versus Valsartan in HFmrEF and HFpEF with a Worsening Heart Failure Event. Mentz RJ, Ward JH, Hernandez AF, LePage S, Morrow DA, Sarwat S, Sharma K, Solomon SD, Starling RC, Velazquez EJ, Williamson K, Zieroth S, Braunwald E. J Card Fail. 2023 Feb 14:S1071-9164(23)00040-4. doi: 10.1016/j.cardfail.2023.02.001.

Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Gaba P, O’Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MS. Circulation. 2023 Feb 13. doi: 10.1161/CIRCULATIONAHA.122.063399.

Site-level variability in the processes of care and outcomes over time among patients with COVID-19 and myocardial injury: Insights from the American Heart Association’s COVID-19 Cardiovascular Disease Registry. Sammour YM, Spertus JA, Kennedy K, Morrow DA, Daniels LB, Jones P, Alger H, Stevens L, Shah A, Goel SS, de Lemos JA, Hayek SS, Sutton NR, Kleiman NS. Am Heart J Plus. 2023 Mar;27:100265. doi: 10.1016/j.ahjo.2023.100265. Epub 2023 Feb 3.

Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. Oliver W, Giugliano RP. Curr Atheroscler Rep. 2023 Feb 10. doi: 10.1007/s11883-023-01084-4.

Timing of Active Left Ventricular Unloading in Patients on Venoarterial Extracorporeal Membrane Oxygenation Therapy. Schrage B, Sundermeyer J, Blankenberg S, Colson P, Eckner D, Eden M, Eitel I, Frank D, Frey N, Graf T, Kirchhof P, Kupka D, Landmesser U, Linke A, Majunke N, Mangner N, Maniuc O, Mierke J, Möbius-Winkler S, Morrow DA, Mourad M, Nordbeck P, Orban M, Pappalardo F, Patel SM, Pauschinger M, Pazzanese V, Radakovic D, Schulze PC, Scherer C, Schwinger RHG, Skurk C, Thiele H, Varshney A, Wechsler L, Westermann D. JACC Heart Fail. 2022 Dec 13:S2213-1779(22)00657-6. doi: 10.1016/j.jchf.2022.11.005.

Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF.
Vascul Pharmacol. 2023 Jan 28;149:107145. doi: 10.1016/j.vph.2023.107145.

On the brink of the new year, on the brink of a new era: European Heart Journal Acute CardioVascular Care goes online only. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2023 Jan 27;12(1):1.

Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Clin Cardiol. 2023 Jan 24. doi: 10.1002/clc.23972.

Multi-Marker Risk Assessment in Patients Hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Bhatt AS, Daniels LB, de Lemos J, Goodrich E, Bohula EA, Morrow DA. Am Heart J. 2023 Jan 17:S0002-8703(22)00334-9. doi: 10.1016/j.ahj.2022.12.014.

OCT utilization: Summary statistics from the LightLab clinical initiative. Raja A, Osborn EA, Bergmark BA, Croce KD, Poulin MF, Tamez H, West N, Buccola J, Meinen J, Secemsky EA; LightLab Clinical Initiative Investigators. Catheter Cardiovasc Interv. 2022 Nov;100 Suppl 1:S36-S43.

High-Sensitivity Cardiac Troponin Assays in U.S. Hospitals: A Report Card. Gulati M, Berg DD. J Am Coll Cardiol. 2023 Jan 24;81(3):220-223.

Short interfering RNA: a rapidly developing drug class. Braunwald E. Eur Heart J. 2022 Dec 7;43(46):4772-4774.

Control of residual dyslipidaemic risk. Braunwald E. Eur Heart J. 2022 Oct 14;43(39):3824-3825.

Air pollution: challenges and opportunities for cardiology. Braunwald E. Eur Heart J. 2023 Jan 7:ehac791. doi: 10.1093/eurheartj/ehac791.

Bridging Strategies and Cardiac Replacement Outcomes in Patients with Acute Decompensated Heart Failure-Related Cardiogenic Shock. Varshney AS, Berg DD, Zhou G, Sinnenberg L, Hirji S, DeFilippis EM, Mallidi HR, Morrow DA, Rinewalt D, Givertz MM. Eur J Heart Fail. 2023 Jan 4. doi: 10.1002/ejhf.2762.

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PS. JACC Heart Fail. 2022 Oct 20:S2213-1779(22)00571-6. doi: 10.1016/j.jchf.2022.09.004.

Acute cardiovascular care in the Emergency Department and beyond: A call for interdisciplinary collaboration in clinical research. Platz E, Morrow DA, Verbrugge FH, Vranckx P, Cullen L. Eur Heart J Acute Cardiovasc Care. 2022 Dec 31:zuac170. doi: 10.1093/ehjacc/zuac170.

Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, Roselli C, Kamatani Y, Komuro I, Aragam KG, Butterworth AS, Ito K, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. JAMA Cardiol. 2022 Dec 28. doi: 10.1001/jamacardio.2022.4466.

Prognostic interpretation of serial high-sensitivity cardiac troponin in patients presenting with suspected acute coronary syndrome. Morrow DA. Eur Heart J. 2022 Dec 20:ehac749. doi: 10.1093/eurheartj/ehac749.

Characteristics, Therapies, and Outcomes of In-Hospital vs Out-of-Hospital Cardiac Arrest in Patients Presenting to Cardiac Intensive Care Units: From the Critical Care Cardiology Trials Network (CCCTN). Carnicelli AP, Keane R, Brown KM, Loriaux DB, Kendsersky P, Alviar CL, Arps K, Berg DD, Bohula EA, Burke JA, Dixson JA, Gerber DA, Goldfarb M, Granger CB, Guo J, Harrison RW, Kontos M, Lawler PR, Elliott Miller P, Nativi-Nicolau J, Kristin Newby L, Racharla L, Roswell RO, Shah KS, Sinha SS, Solomon MA, Teuteberg J, Wong G, van Diepen S, Katz JN, Morrow DA. Resuscitation. 2022 Dec 12:S0300-9572(22)00737-7. doi: 10.1016/j.resuscitation.2022.12.002.

Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta SR, Pollack CV, Sabate M, Rao SV, Parkhomenko A, Feldman LJ, Sayah N, Sabatine MS, Steg PG; TAO investigators. Am J Cardiol. 2022 Dec 6;188:95-101. doi: 10.1016/j.amjcard.2022.11.013.

Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM, Sherliker P, Koyama S, Ishigaki K, Åsvold BO, Brown MR, Brumpton B, de Vries PS, Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Güldener U, Haider SMI, Helgadottir A, Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S, Munz M, Murgia F, Nielsen JB, Nöthen MM, Pang S, Reinberger T, Schnitzler G, Smedley D, Thorleifsson G, von Scheidt M, Ulirsch JC; Biobank Japan; EPIC-CVD, Arnar DO, Burtt NP, Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Björkegren JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT, Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J, Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS; CARDIoGRAMplusC4D Consortium. Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6.

Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry. Patel SM, Berg DD, Bohula EA, Baird-Zars VM, Barnett CF, Barsness GW, Chaudhry SP, Daniels LB, van Diepen S, Ghafghazi S, Goldfarb MJ, Jentzer JC, Katz JN, Kenigsberg BB, Lawler PR, Miller PE, Papolos AI, Park JG, Potter BJ, Prasad R, Singam NSV, Sinha SS, Solomon MA, Teuteberg JJ, Morrow DA; CCCTN Investigators. Circ Heart Fail. 2022 Dec 2:e009714. doi: 10.1161/CIRCHEARTFAILURE.122.009714.

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn A.
Diabetes Care. 2022 Nov 18:dc221318. doi: 10.2337/dc22-1318.

Decision-Making During Percutaneous Coronary Intervention Guided by Optical Coherence Tomography: Insights From the LightLab Initiative. Bergmark B, Dallan LAP, Pereira GTR, Kuder JF, Murphy SA, Buccola J, Wollmuth J, Lopez J, Spinelli J, Meinen J, West NEJ, Croce K; LightLab Initiative Investigators.
Circ Cardiovasc Interv. 2022 Nov;15(11):872-881. doi: 10.1161/CIRCINTERVENTIONS.122.011851.

Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries. Mishra A et. al. including Kamanu FK, Marston NA, Sabatine MS, Nature. 2022 Nov 14. doi: 10.1038/s41586-022-05492-5.

Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Eur Heart J. 2022 Nov 11:ehac402. doi: 10.1093/eurheartj/ehac402.

The Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock (ECMO-CS) Trial in Perspective. Morrow DA, van Diepen S. Eur Heart J Acute Cardiovasc Care. 2022 Nov 9:zuac145. doi: 10.1093/ehjacc/zuac145.

Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network. Blood AJ, Cannon CP, Gordon WJ, Mailly C, MacLean T, Subramaniam S, Tucci M, Crossen J, Nichols H, Wagholikar KB, Zelle D, McPartlin M, Matta LS, Oates M, Aronson S, Murphy S, Landman A, Fisher NDL, Gaziano TA, Plutzky J, Scirica BM. JAMA Cardiol. 2022 Nov 9. doi: 10.1001/jamacardio.2022.4018.

Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER. Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, Vardeny O, O’Meara E, Zieroth S, Katova T, McGrath MM, Pouleur AC, Jhund PS, Desai AS, Inzucchi SE, Kosiborod MN, de Boer RA, Køber L, Sabatine MS, Martinez FA, Ponikowski P, Shah SJ, Hernandez AF, Langkilde AM, McMurray JJV, Solomon SD, Lam CSP. Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Docherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. JACC Asia. 2022 Mar 29;2(2):139-153. doi: 10.1016/j.jacasi.2022.02.004. eCollection 2022 Apr.

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. Michelle L O’Donoghue 1, Robert S Rosenson 1, Baris Gencer 1, J Antonio G López 1, Norman E Lepor 1, Seth J Baum 1, Elmer Stout 1, Daniel Gaudet 1, Beat Knusel 1, Julia F Kuder 1, Xinhui Ran 1, Sabina A Murphy 1, Huei Wang 1, You Wu 1, Helina Kassahun 1, Marc S Sabatine 1, OCEAN(a)-DOSE Trial Investigators. N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2211023.

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, MJ Landray, KJ Mayne, SYA Ng, D Preiss, AJ Roddick, N Staplin, D Zhu, SD Anker, DL Bhatt, M Brueckmann, J Butler, DZI Cherney, JB Green, SJ Hauske, HJL Heerspink, WG Herrington, SE Inzucchi, MJ Jardine, C-C Liu, KW Mahaffey, FR McCausland, DK McGuire, JJV McMurray, B Neal, BL Neuen, M Packer, V Perkovic, MS Sabatine, SD Solomon, M Vaduganathan, C Wanner, DC Wheeler, SD Wiviott, F Zannad. Lancet. 2022 Nov 19;400(10365):1788-1801.

The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, Granger C, Køber L, Maggioni A, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Ducrocq G, Berwanger O, De Pasquale CG, Landmesser U, Petrie M, Leng DSK, van der Meer P, Lefkowitz M, Zhou Y, Braunwald E. Circulation. 2022 Nov 2. doi: 10.1161/CIRCULATIONAHA.122.060841.

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. Caso V, de Groot JR, Sanmartin Fernandez M, Segura T, Blomström-Lundqvist C, Hargroves D, Antoniou S, Williams H, Worsley A, Harris J, Caleyachetty A, Vardar B, Field P, Ruff CT. Heart. 2022 Oct 31:heartjnl-2022-321114. doi: 10.1136/heartjnl-2022-321114.

Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O’Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MS. Eur Heart J. 2022 Oct 28:ehac577. doi: 10.1093/eurheartj/ehac577.

Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock. Damluji AA, Tehrani B, Sinha SS, Samsky MD, Henry TD, Thiele H, West NEJ, Senatore FF, Truesdell AG, Dangas GD, Smilowitz NR, Amin AP, deVore AD, Moazami N, Cigarroa JE, Rao SV, Krucoff MW, Morrow DA, Gilchrist IC. JACC Cardiovasc Interv. 2022 Oct 24;15(20):2003-2019.

Atrial Fibrillation – What Is It and How Is It Treated? Antman EM, Leopold JA, Sauer WH, Zei PC. N Engl J Med. 2022 Oct 20;387(16):e38. doi: 10.1056/NEJMp2212939.

Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. Patel SM, Qamar A, Giugliano RP, Jarolim P, Marston NA, Park JG, Blazing MA, Cannon CP, Braunwald E, Morrow DA. JAMA Cardiol. 2022 Oct 19. doi: 10.1001/jamacardio.2022.3627. Online ahead of print.

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Cholesterol Treatment Trialists’ Collaboration. Meta-Analysis Lancet. 2022 Sep 10;400(10355):832-845. doi: 10.1016/S0140-6736(22)01545-8.

Oxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients: From Pathophysiology to Clinical Practice. Thomas A, van Diepen S, Beekman R, Sinha SS, Brusca SB, Alviar CL, Jentzer J, Bohula EA, Katz JN, Shahu A, Barnett C, Morrow DA, Gilmore EJ, Solomon MA, Miller PE.
JACC Adv. 2022 Aug;1(3):100065. doi: 10.1016/j.jacadv.2022.100065.

The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function – A systematic review. Huqi A, Zoccali C, Giugliano RP, Caterina R. Vascul Pharmacol. 2022 Oct 3:107123. doi: 10.1016/j.vph.2022.107123.

Atrial Fibrillation and Catheter Ablation. Antman EM, Leopold JA, Sauer WH, Zei PC. N Engl J Med. 2022 Oct 6;387(14):e31. doi: 10.1056/NEJMp2212526.

Stroke genetics informs drug discovery and risk prediction across ancestries. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, He Y, Georgakis MK, Caro I, Krebs K, Liaw YC, Vaura FC, Lin K, Winsvold BS, Srinivasasainagendra V, Parodi L, Bae HJ, Chauhan G, Chong MR, Tomppo L, Akinyemi R, Roshchupkin GV, Habib N, Jee YH, Thomassen JQ, Abedi V, Cárcel-Márquez J, Nygaard M, Leonard HL, Yang C, Yonova-Doing E, Knol MJ, Lewis AJ, Judy RL, Ago T, Amouyel P, Armstrong ND, Bakker MK, Bartz TM, Bennett DA, Bis JC, Bordes C, Børte S, Cain A, Ridker PM, Cho K, Chen Z, Cruchaga C, Cole JW, de Jager PL, de Cid R, Endres M, Ferreira LE, Geerlings MI, Gasca NC, Gudnason V, Hata J, He J, Heath AK, Ho YL, Havulinna AS, Hopewell JC, Hyacinth HI, Inouye M, Jacob MA, Jeon CE, Jern C, Kamouchi M, Keene KL, Kitazono T, Kittner SJ, Konuma T, Kumar A, Lacaze P, Launer LJ, Lee KJ, Lepik K, Li J, Li L, Manichaikul A, Markus HS, Marston NA, Meitinger T, Mitchell BD, Montellano FA, Morisaki T, Mosley TH, Nalls MA, Nordestgaard BG, O’Donnell MJ, Okada Y, Onland-Moret NC, Ovbiagele B, Peters A, Psaty BM, Rich SS, Rosand J, Sabatine MS, Sacco RL, Saleheen D, Sandset EC, Salomaa V, Sargurupremraj M, Sasaki M, Satizabal CL, Schmidt CO, Shimizu A, Smith NL, Sloane KL, Sutoh Y, Sun YV, Tanno K, Tiedt S, Tatlisumak T, Torres-Aguila NP, Tiwari HK, Trégouët DA, Trompet S, Tuladhar AM, Tybjærg-Hansen A, van Vugt M, Vibo R, Verma SS, Wiggins KL, Wennberg P, Woo D, Wilson PWF, Xu H, Yang Q, Yoon K; COMPASS Consortium; INVENT Consortium; Dutch Parelsnoer Initiative (PSI) Cerebrovascular Disease Study Group; Estonian Biobank; PRECISEQ Consortium; FinnGen Consortium; NINDS Stroke Genetics Network (SiGN); MEGASTROKE Consortium; SIREN Consortium; China Kadoorie Biobank Collaborative Group; VA Million Veteran Program; International Stroke Genetics Consortium (ISGC); Biobank Japan; CHARGE Consortium; GIGASTROKE Consortium, Millwood IY, Gieger C, Ninomiya T, Grabe HJ, Jukema JW, Rissanen IL, Strbian D, Kim YJ, Chen PH, Mayerhofer E, Howson JMM, Irvin MR, Adams H, Wassertheil-Smoller S, Christensen K, Ikram MA, Rundek T, Worrall BB, Lathrop GM, Riaz M, Simonsick EM, Kõrv J, França PHC, Zand R, Prasad K, Frikke-Schmidt R, de Leeuw FE, Liman T, Haeusler KG, Ruigrok YM, Heuschmann PU, Longstreth WT, Jung KJ, Bastarache L, Paré G, Damrauer SM, Chasman DI, Rotter JI, Anderson CD, Zwart JA, Niiranen TJ, Fornage M, Liaw YP, Seshadri S, Fernández-Cadenas I, Walters RG, Ruff CT, Owolabi MO, Huffman JE, Milani L, Kamatani Y, Dichgans M, Debette S. Nature. 2022 Sep 30. doi: 10.1038/s41586-022-05165-3.

Publisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SA. Nat Commun. 2022 Sep 30;13(1):5767. doi: 10.1038/s41467-022-33534-z.

A remote hypertension management program clinical algorithm. Nichols H, Cannon CP, Scirica BM, Fisher NDL. Clin Cardiol. 2022 Sep 24. doi: 10.1002/clc.23919.

Inhibitors of factor XI: game changers of anti-thrombotic therapy. Braunwald E. Eur Heart J. 2022 Sep 23:ehac524. doi: 10.1093/eurheartj/ehac524.

Mortality and Heart Failure Hospitalization Among Young Adults With and Without Cardiogenic Shock after Acute Myocardial Infarction. Siddiqi HK, DeFilippis EM, Biery DW, Singh A, Wu WY, Divakaran S, Berman A, Rizk T, Januzzi JL, Bohula E, Stewart G, Carli MD, Bhatt DL, Blankstein R. J Card Fail. 2022 Sep 18:S1071-9164(22)00710-2. doi: 10.1016/j.cardfail.2022.08.012.

Blood pressure and oxygenation targets after out-of-hospital cardiac arrest-trial (BOX). van Diepen S, Tavazzi G, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2022 Sep 15:zuac109. doi: 10.1093/ehjacc/zuac109.

Oxygenation targets in post-resuscitation care: a perspective of the BOX randomized clinical trial. Tavazzi G, van Diepen S, Morrow D. Eur Heart J Acute Cardiovasc Care. 2022 Sep 12:zuac110. doi: 10.1093/ehjacc/zuac110.

A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods. Wronski ML, Plessow F, Kerem L, Asanza E, O’Donoghue ML, Stanford FC, Bredella MA, Torriani M, Soukas AA, Kheterpal A, Eddy KT, Holmes TM, Deckersbach T, Vangel M, Holsen LM, Lawson EA. Contemp Clin Trials. 2022 Sep 7:106909. doi: 10.1016/j.cct.2022.106909.

MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. McCoy MG, Jamaiyar A, Sausen G, Cheng HS, Pérez-Cremades D, Zhuang R, Chen J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MW. Angiogenesis. 2022 Sep 8. doi: 10.1007/s10456-022-09856-3.

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Adamson C, Cowan LM, de Boer RA, Diez M, Drożdż J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Lindholm D, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV, Jhund PS. Eur J Heart Fail. 2022 Aug 6. doi: 10.1002/ejhf.2649.

Sacubitril/Valsartan Versus Ramipril For Patients With Acute Myocardial Infarction: Win-Ratio Analysis of the PARADISE_MI Trial. Berwanger O, Pfeffer M, Claggett B, Jering KS, Maggioni AP, Steg PG, Mehran R, Lewis EF, Zhou Y, van der Meer P, De Pasquale C, Merkely B, Filippatos G, McMurray JJV, Granger CB, Solomon SD, Braunwald E. Eur J Heart Fail. 2022 Aug 29. doi: 10.1002/ejhf.2663.

I2b2-etl: Python application for importing Electronic Health Data into the Informatics for Integrating Biology and the Bedside Platform. Wagholikar KB, Ainsworth L, Zelle D, Chaney K, Mendis M, Klann J, Blood AJ, Miller A, Chulyadyo R, Oates M, Gordon WJ, Aronson SJ, Scirica BM, Murphy SN. Bioinformatics. 2022 Sep 2:btac595. doi: 10.1093/bioinformatics/btac595.

Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SA. Nat Commun. 2022 Aug 30;13(1):5106. doi: 10.1038/s41467-022-32009-5.

Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Murphy SA, Spinar J, Oude Ophuis T, Kiss RG, Lopez-Sendon J, Averkov O, Wheatcroft SB, Kubica J, Carlos Nicolau J, Furtado RHM, Abuhatzira L, Hirshberg B, Omar SA, Vavere AL, Chang YT, George RT, Sabatine MS. Circulation. 2022 Aug 30:101161CIRCULATIONAHA122059325. doi: 10.1161/CIRCULATIONAHA.122.059325.

Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT. Bohula EA, Berg DD, Lopes MS, Connors JM, Babar I, Barnett CF, Chaudhry SP, Chopra A, Ginete W, Ieong MH, Katz JN, Kim EY, Kuder JF, Mazza E, McLean D, Mosier JM, Moskowitz A, Murphy SA, O’Donoghue ML, Park JG, Prasad R, Ruff CT, Shahrour MN, Sinha SS, Wiviott SD, Van Diepen S, Zainea M, Baird-Zars V, Sabatine MS, Morrow DA. Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.061533.

Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease. O’Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech AC, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, Lopez JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MS. Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.061620.

Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJV. Nat Med. 2022 Aug 27. doi: 10.1038/s41591-022-01971-4.

Critical Care Cardiology Trials Network (CCCTN): a cohort profile. Metkus TS, Baird-Zars VM, Alfonso CE, Alviar CL, Barnett CF, Barsness GW, Berg DD, Bertic M, Bohula EA, Burke J, Burstein B, Chaudhry SP, Cooper HA, Daniels LB, Fordyce CB, Ghafghazi S, Goldfarb M, Katz JN, Keeley EC, Keller NM, Kenigsberg B, Kontos MC, Kwon Y, Lawler PR, Leibner E, Liu S, Menon V, Miller PE, Newby LK, O’Brien CG, Papolos AI, Pierce MJ, Prasad R, Pisani B, Potter BJ, Roswell RO, Sinha SS, Shah KS, Smith TD, Snell RJ, So D, Solomon MA, Ternus BW, Teuteberg JJ, van Diepen S, Zakaria S, Morrow DA. Eur Heart J Qual Care Clin Outcomes. 2022 Aug 27:qcac055. doi: 10.1093/ehjqcco/qcac055.

Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. Kondo T, Abdul-Rahim AH, Talebi A, Abraham WT, Desai AS, Dickstein K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Packer M, Petrie M, Ponikowski P, Rouleau JL, Sabatine MS, Swedberg K, Zile MR, Solomon SD, Jhund PS, McMurray JJ. Eur Heart J. 2022 Aug 26:ehac487. doi: 10.1093/eurheartj/ehac487.

Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Patel SM, Palazzolo MG, Murphy SA, Antman EM, Braunwald E, Lanz HJ, Lip GYH, Giugliano RP, Ruff CT. Europace. 2022 Aug 26:euac082. doi: 10.1093/europace/euac082.

Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. Fagundes A Jr, Morrow DA, Oyama K, Furtado RHM, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Keech AC, Sever P, Giugliano RP, Sabatine MS, Bergmark BA. J Am Coll Cardiol. 2022 Aug 30;80(9):887-897. doi: 10.1016/j.jacc.2022.05.051.

Short interfering RNA: a rapidly developing drug class. Braunwald E. Eur Heart J. 2022 Aug 25:ehac461. doi: 10.1093/eurheartj/ehac461.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes-Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine MS. Diabetes Care. 2022 Aug 23:dc220382. doi: 10.2337/dc22-0382.

Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration? Huqi A, Zoccali C, Giugliano RP, De Caterina R. Eur Heart J. 2022 Aug 19:ehac450. doi: 10.1093/eurheartj/ehac450.

A polygenic risk score predicts atrial fibrillation in cardiovascular disease. Marston NA, Garfinkel AC, Kamanu FK, Melloni GM, Roselli C, Jarolim P, Berg DD, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O’Donoghue ML, Raz I, Scirica BM, Braunwald E, Morrow DA, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. Eur Heart J. 2022 Aug 18:ehac460. doi: 10.1093/eurheartj/ehac460.

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Docherty KF, Welsh P, Verma S, De Boer RA, O’Meara E, Bengtsson O, Køber L, Kosiborod MN, Hammarstedt A, Langkilde AM, Lindholm D, Little DJ, Sjöstrand M, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Schou M, Solomon SD, Sattar N, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060511. doi: 10.1161/CIRCULATIONAHA.122.060511.

Glucose-Insulin-Potassium Therapy for Acute Myocardial Infarction: 50 Years On and Time for a Relook. Udelson JE, Selker HP, Braunwald E. Circulation. 2022 Aug 16;146(7):503-505. doi: 10.1161/CIRCULATIONAHA.121.058740.

Cardiac Xenotransplantation: Another Historic First? Braunwald E. JACC Basic Transl Sci. 2022 Jul 25;7(7):743-744. doi: 10.1016/j.jacbts.2022.06.013.

Anticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP. Natarajan P, Sabatine MS. JAMA Cardiol. 2022 Aug 3. doi: 10.1001/jamacardio.2022.2342.

Atrial amyloidosis: mechanisms and clinical manifestations. Vergaro G, Aimo A, Rapezzi C, Castiglione V, Fabiani I, Pucci A, Buda G, Passino C, Lupón J, Bayes-Genis A, Emdin M, Braunwald E. Eur J Heart Fail. 2022 Aug 3. doi: 10.1002/ejhf.2650.

Catheter-directed interventions for pulmonary embolism. Kochar A, Bergmark BA. Eur Heart J Acute Cardiovasc Care. 2022 Jul 29:zuac089. doi: 10.1093/ehjacc/zuac089.

Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. Butt JH, Dewan P, DeFilippis EM, Biering-Sørensen T, Docherty KF, Jhund PS, Kosiborod MN, Martinez FA, Bengtsson O, Johansen ND, Langkilde AM, Sjöstrand M, Vaduganathan M, Solomon SD, Sabatine MS, Køber L, Fiuzat M, McMurray JJV. JACC Heart Fail. 2022 Aug;10(8):543-555. doi: 10.1016/j.jchf.2022.03.009.

Use of automatic SQL generation interface to enhance transparency and validity of health-data analysis. Wagholikar KB, Zelle D, Ainsworth L, Chaney K, Blood AJ, Miller A, Chulyadyo R, Oates M, Gordon WJ, Aronson SJ, Scirica BM, Murphy SN. Inform Med Unlocked. 2022;31:100996. doi: 10.1016/j.imu.2022.100996.

Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry. Fagundes A Jr, Berg DD, Park JG, Baird-Zars VM, Newby LK, Barsness GW, Miller PE, van Diepen S, Katz JN, Phreaner N, Roswell RO, Menon V, Daniels LB, Morrow DA, Bohula EA; CCCTN Investigators. Circ Cardiovasc Qual Outcomes. 2022 Jul 5:101161CIRCOUTCOMES121008652. doi: 10.1161/CIRCOUTCOMES.121.008652.

Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. JAMA Cardiol. 2022 Jul 20. doi: 10.1001/jamacardio.2022.2006.

Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Clin Cardiol. 2022 Jul 19. doi: 10.1002/clc.23843.

The Intersection between Heart Failure and Critical Care Cardiology: An International Perspective on Structure, Staffing, and Design Considerations. Sinha SS, Bohula EA, van Diepen S, Leonardi S, Mebazaa A, Proudfoot AG, Sionis A, Chia YW, Zampieri FG, Lopes RD, Katz JN. J Card Fail. 2022 Jul 14:S1071-9164(22)00579-6. doi: 10.1016/j.cardfail.2022.06.007.

Control of residual dyslipidaemic risk. Braunwald E. Eur Heart J. 2022 Jul 5:ehac359. doi: 10.1093/eurheartj/ehac359.

Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure: Analysis of the LIFE Trial Run-In. Vader JM, Givertz MM, Starling RC, McNulty SE, Anstrom KJ, Desvigne-Nickens P, Hernandez AF, Braunwald E, Mann DL; LIFE Investigators. JACC Heart Fail. 2022 Jul;10(7):449-456.

Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo ML. J Clin Lipidol. 2022 Jun 6:S1933-2874(22)00174-X. doi: 10.1016/j.jacl.2022.05.069.

Leaders in cardiovascular research: Eugene Braunwald. Braunwald E, Guzik TJ. Cardiovasc Res. 2022 Jun 22;118(7):e48-e50. doi: 10.1093/cvr/cvac033.

Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. Aoki Y, Cabrera CS, Ouwens M, Bamberg K, Nyström J, Raz I, Scirica BM, Hamrén B, Greasley PJ, Rekić D. PLoS One. 2022 Jun 21;17(6):e0269970. doi: 10.1371/journal.pone.0269970.

Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies.  Al. et O’Donoghue ML. Int. 2022 Jun 15:S0085-2538(22)00454-9. doi: 10.1016/j.kint.2022.05.021.

Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MS. Clin Cardiol. 2022 Jun 17. doi: 10.1002/clc.23844.

Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals. Al. et O’Donoghue ML. Commun Biol. 2022 Jun 13;5(1):580. doi: 10.1038/s42003-022-03448-z.

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Capodanno D, Baber U, Bhatt DL, Collet JP, Dangas G, Franchi F, Gibson CM, Gwon HC, Kastrati A, Kimura T, Lemos PA, Lopes RD, Mehran R, O’Donoghue ML, Rao SV, Rollini F, Serruys PW, Steg PG, Storey RF, Valgimigli M, Vranckx P, Watanabe H, Windecker S, Angiolillo DJ. Nat Rev Cardiol. 2022 Jun 13. doi: 10.1038/s41569-022-00725-6.

Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. Schwartz GG, Giugliano RP. Curr Opin Lipidol. 2022 Jun 1;33(3):147-159. doi: 10.1097/MOL.0000000000000830.

Cardiac xenotransplantation: a new path for the treatment of advanced heart failure? Braunwald E. Eur Heart J. 2022 Jun 4:ehac276. doi: 10.1093/eurheartj/ehac276.

“The Doctor Is Out”: New Tactics and Soldiers for Our Losing Battle Against Hypertension. Brook RD, Scirica BM, Levy PD. Circulation. 2022 May 31;145(22):1629-1631. doi: 10.1161/CIRCULATIONAHA.122.059674.

Gliflozins in the Management of Cardiovascular Disease. Braunwald E. N Engl J Med. 2022 May 26;386(21):2024-2034. doi: 10.1056/NEJMra2115011.

Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF. Selvaraj S, Fu Z, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Newgard CB, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Lanfear DE, Nassif ME, Javaheri A, Mentz RJ, Kosiborod MN, Shah SH. Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.

Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. Hofer F, Pailer U, Sulzgruber P, Gerges C, Winter MP, Giugliano RP, Gottsauner-Wolf M, Hülsmann M, Kazem N, Koller L, Schönbauer R, Niessner A, Hengstenberg C, Zelniker TA. ESC Heart Fail. 2022 May 20. doi: 10.1002/ehf2.13930.

Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. O’Donoghue ML, López JAG, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MS. Am Heart J. 2022 May 6:S0002-8703(22)00086-2. doi: 10.1016/j.ahj.2022.05.004.

Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. Duarte Lau F, Giugliano RP. JAMA Cardiol. 2022 May 18. doi: 10.1001/jamacardio.2022.0987.

Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. Bikdeli B, Piazza G, Jimenez D, Muriel A, Wang Y, Khairani CD, Rosovsky RP, Mehdipoor G, O’Donoghue ML, Spagnolo P, Dreyer RP, Bertoletti L, López-Jiménez L, Núñez MJ, Blanco-Molina Á, Bates SM, Gerhard-Herman M, Goldhaber SZ, Monreal M, Krumholz HM. Thromb Res. 2022 May 4;214:122-131. doi: 10.1016/j.thromres.2022.04.019.

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.

Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?-Reply. Mann DL, Hernandez AF, Braunwald E. JAMA Cardiol. 2022 May 4. doi: 10.1001/jamacardio.2022.0787.

Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. JACC Heart Fail. 2022 May;10(5):306-318. doi: 10.1016/j.jchf.2022.01.019.

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Giugliano RP, Martens FMAC, Gibson CM, Ballantyne CM; REDUCE-IT Investigators. J Am Coll Cardiol. 2022 May 3;79(17):1660-1671. doi: 10.1016/j.jacc.2022.02.035.

Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. J Am Heart Assoc. 2022 Apr 27:e022198. doi: 10.1161/JAHA.121.022198.

Epidemiology and Management of ST-Segment-Elevation Myocardial Infarction in Patients With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Bhatt AS, Varshney AS, Goodrich EL, Gong J, Ginder C, Senman BC, Johnson M, Butler K, Woolley AE, de Lemos JA, Morrow DA, Bohula EA. J Am Heart Assoc. 2022 Apr 26:e024451. doi: 10.1161/JAHA.121.024451.

Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Butt JH, Dewan P, Merkely B, Belohlávek J, Drożdż J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJV. Ann Intern Med. 2022 Apr 26. doi: 10.7326/M21-4776.
PMID: 35467935

Initial Decline (“dip”) in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF. Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Vaduganathan M, Jhund PS, McMurray JJV. Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.

Cardiac cell therapy: a call for action. Braunwald E. Eur Heart J. 2022 Apr 13:ehac188. doi: 10.1093/eurheartj/ehac188.

Novel three-stent strategy in left-main coronary artery trifurcation disease – Combination of DK crush and Culotte techniques. Sung JG, Kochar A, Croce KJ, Bergmark BA. Cardiovasc Revasc Med. 2022 Apr 2:S1553-8389(22)00172-5. doi: 10.1016/j.carrev.2022.03.034.

No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. Korthauer LE, Giugliano RP, Guo J, Sabatine MS, Sever P, Keech A, Atar D, Kurtz C, Ruff CT, Mach F, Ott BR. PLoS One. 2022 Apr 11;17(4):e0266615. doi: 10.1371/journal.pone.0266615. eCollection 2022.

Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials. Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL. Circulation. 2022 Apr 8. doi: 10.1161/CIRCULATIONAHA.121.057736.

Acute coronary syndromes. Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Lancet. 2022 Apr 2;399(10332):1347-1358. doi: 10.1016/S0140-6736(21)02391-6.
PMID: 35367005 Free PMC article.

Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Brian A. Bergmark, Nicholas A. Marston, Candace R. Bramson, Madelyn Curto, Vesper Ramos, Alexandra Jevne, Julia F. Kuder, Jeong-Gun Park, Sabina A. Murphy, Subodh Verma, Wojtek Wojakowski, Steven G. Terra, Marc S. Sabatine and Stephen D. Wiviott. Circulation. 3 Apr 2022. https://doi.org/10.1161/CIRCULATIONAHA.122.059266.

Sixty-Year Evolution of Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy with Insights From the Historic NIH Surgical Experience to Present. Maron MS, Rosing DR, Braunwald E, Rastegar H, Koethe B, Roberts WC, Maron BJ, Rowin EJ. Am J Cardiol. 2022 Mar 28:S0002-9149(22)00180-1. doi: 10.1016/j.amjcard.2022.02.035.

Antiplatelet therapy after percutaneous coronary intervention. Angiolillo DJ, Galli M, Collet JP, Kastrati A, O’Donoghue ML. EuroIntervention. 2022 Apr 1;17(17):e1371-e1396. doi: 10.4244/EIJ-D-21-00904.

Appointment as patient advocacy associate editor. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2022 Mar 15:zuac027. doi: 10.1093/ehjacc/zuac027.

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE‐IT Investigators. J Am Heart Assoc. 2022 Mar 9:e022937. doi: 10.1161/JAHA.121.022937.

Tirzepatide for diabetes: on track to SURPASS current therapy. Moura FA, Scirica BM, Ruff CT. Nat Med. 2022 Mar 8. doi: 10.1038/s41591-022-01733-2.

Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases. Leopold JA, Antman EM. Front Cardiovasc Med. 2022 Feb 17;9:814610. doi: 10.3389/fcvm.2022.814610.

Changing the Trajectory of Heart Failure and Kidney Disease. Rangaswami J, Bhalla V, Chertow G, Harrington R, Staruschenko A, Tuttle K, Braunwald E. Clin J Am Soc Nephrol. 2022 Mar 1:CJN.00470122. doi: 10.2215/CJN.00470122.

Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Scanavini-Filho MA, Berwanger O, Matthias W, Aguiar MO, Chiang HP, Azevedo L, Baracioli LM, Lima FG, Furtado RHM, Dalcoquio TF, Menezes FR, Ferrari AG, de Luca F, Giugliano RP, Goodman S, Nicolau JC. Adv Ther. 2022 Feb 26. doi: 10.1007/s12325-022-02061-0.

Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Furtado RHM, Fagundes AA Jr, Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BA. Circ Cardiovasc Interv. 2022 Feb 25:CIRCINTERVENTIONS121011382. doi: 10.1161/CIRCINTERVENTIONS.121.011382.

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Giugliano RP. Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A1-A10. doi: 10.1093/eurheartj/suab150. eCollection 2022 Feb.

Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy. O’Donoghue ML, Marston NA. Eur Heart J. 2022 Feb 15:ehac046. doi: 10.1093/eurheartj/ehac046.

Sodium and Health: Old Myths and a Controversy Based on Denial. Cappuccio FP, Campbell NRC, He FJ, Jacobson MF, MacGregor GA, Antman E, Appel LJ, Arcand J, Blanco-Metzler A, Cook NR, Guichon JR, L’Abbè MR, Lackland DT, Lang T, McLean RM, Miglinas M, Mitchell I, Sacks FM, Sever PS, Stampfer M, Strazzullo P, Sunman W, Webster J, Whelton PK, Willett W. Curr Nutr Rep. 2022 Feb 14. doi: 10.1007/s13668-021-00383-z.

Heart failure: a 70 year Odyssey†. Braunwald E. Eur Heart J. 2022 Feb 15:ehac058. doi: 10.1093/eurheartj/ehac058.

The Road Not Yet Traveled: Distinction in Critical Care Cardiology through the Advanced Heart Failure and Transplant Cardiology Training Pathway. Carnicelli AP, Blumer V, Genovese L, Gage A, Agarwal R, Lakdawala NK, Bohula E, Katz JN. J Card Fail. 2022 Feb;28(2):339-342. doi: 10.1016/j.cardfail.2021.07.014.

Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Reply.
Pfeffer MA, Jering KS, Braunwald E. N Engl J Med. 2022 Feb 10;386(6):603. doi: 10.1056/NEJMc2119225.

A pragmatic lab-based tool for risk assessment in cardiac critical care: data from the Critical Care Cardiology Trials Network (CCCTN) Registry. Patel SM, Jentzer JC, Alviar CL, Baird-Zars VM, Barsness GW, Berg DD, Bohula EA, Daniels LB, DeFilippis AP, Keeley EC, Kontos MC, Lawler PR, Miller PE, Park JG, Roswell RO, Solomon MA, van Diepen S, Katz JN, Morrow DA.
Eur Heart J Acute Cardiovasc Care. 2022 Feb 3:zuac012. doi: 10.1093/ehjacc/zuac012.

Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. Docherty KF, Simpson J, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Sjöstrand M, Lindholm D, Langkilde AM, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. JACC Heart Fail. 2022 Feb;10(2):104-118. doi: 10.1016/j.jchf.2021.09.002.

Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. Fordyce CB, Giugliano RP, Cannon CP, Roe MT, Sharma A, Page C, White JA, Lokhnygina Y, Braunwald E, Blazing MA. J Am Heart Assoc. 2022 Feb 3:e022733. doi: 10.1161/JAHA.121.022733.

The inclusion of augmented intelligence in medicine: A framework for successful implementation. Bazoukis G, Hall J, Loscalzo J, Antman EM, Fuster V, Armoundas AA. Cell Rep Med. 2022 Jan 18;3(1):100485. doi: 10.1016/j.xcrm.2021.100485. eCollection 2022 Jan 18.

A call to action for translational sciences in COVID-19 and future pandemics. Wan KK, Davis D, Lee TN, Ford-Scheimer SL, Andreu AL, Bietrix F, Bryans J, Castro MT, Chiba N, Faupel-Badger JM, Haynes B, Hirasawa R, Morel CM, Souza TML, Morrow D, Munro T, Newman S, Ussi AE, Zorzal PB, Hall MD, Lo DC, Cutillo CM. Nat Rev Drug Discov. 2022 Jan 28. doi: 10.1038/d41573-022-00020-6.

Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. Oyama K, Giugliano RP, Sabatine MS, Cannon CP, Braunwald E. J Am Coll Cardiol. 2022 Feb 1;79(4):e153. doi: 10.1016/j.jacc.2021.11.018.

Up in the Air. Loewenthal JV, Vaidya A, Duran B, Pozner CN, Scirica BM. N Engl J Med. 2022 Jan 27;386(4):e7. doi: 10.1056/NEJMimc2003326.

Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon HA, Grudzen C, Hochman J, Antman EM. JAMA Netw Open. 2022 Jan 4;5(1):e2147331. doi: 10.1001/jamanetworkopen.2021.47331.

Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. Park H, Tarpey T, Liu M, Goldfeld K, Wu Y, Wu D, Li Y, Zhang J, Ganguly D, Ray Y, Paul SR, Bhattacharya P, Belov A, Huang Y, Villa C, Forshee R, Verdun NC, Yoon HA, Agarwal A, Simonovich VA, Scibona P, Burgos Pratx L, Belloso W, Avendaño-Solá C, Bar KJ, Duarte RF, Hsue PY, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Troxel A, Antman EM, Petkova E. JAMA Netw Open. 2022 Jan 4;5(1):e2147375. doi: 10.1001/jamanetworkopen.2021.47375.

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, De Boer RA, O’Meara E, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Hammarstedt A, Langkilde AM, Sjöstrand M, Lindholm D, Solomon SD, Sattar N, Sabatine MS, McMurray JJV. Eur J Heart Fail. 2022 Jan 22. doi: 10.1002/ejhf.2433.

Epidemiology of Acute Heart Failure in Critically Ill Patients with COVID-19: An Analysis from the Critical Care Cardiology Trials Network. Berg DD, Alviar CL, Bhatt AS, Baird-Zars VM, Barnett CF, Daniels LB, DeFilippis AP, Fagundes A Jr, Katrapati P, Kenigsberg BB, Guo J, Keller N, Lopes MS, Mody A, Papolos AI, Phreaner N, Sedighi R, Sinha SS, Toomu S, Varshney AS, Morrow DA, Bohula EA. J Card Fail. 2022 Jan 17:S1071-9164(22)00007-0. doi: 10.1016/j.cardfail.2021.12.020.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR. Clin Pharmacol Ther. 2022 Jan 16. doi: 10.1002/cpt.2526.

Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Kolkailah AA, Wiviott SD, Raz I, Murphy SA, Mosenzon O, Bhatt DL, Leiter LA, Wilding JPH, Gause-Nilsson I, Sabatine MS, McGuire DK. Diabetes Care. 2022 Jan 12:dc211668. doi: 10.2337/dc21-1668.

Magnetic Resonance Spectroscopy of Hypoxic-Ischemic Encephalopathy After Cardiac Arrest. Lee JW, Sreepada L, Bevers M, Li K, Scirica B, Santana da Silva D, Henderson GV, Bay C, Lin AP. Neurology. 2022 Jan 11:10.1212/WNL.0000000000013297.

Regional Distribution of Brain Injury After Cardiac Arrest: Clinical and Electrographic Correlates. Snider SB, Fischer D, McKeown ME, Cohen AL, Schaper FLWVJ, Amorim E, Fox MD, Scirica B, Bevers MB, Lee JW. Neurology. 2022 Jan 11:10.1212/WNL.0000000000013301.

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Raz I. Diabetes Care. 2022 Jan 10:dc211744. doi: 10.2337/dc21-1744.

Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups. Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, Chen C, Lanz H, Ruff CT, Antman EM, Braunwald E, Giugliano RP. Am Heart J. 2022 Jan 3:S0002-8703(21)00499-3. doi: 10.1016/j.ahj.2021.12.017.

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Am Heart J. 2022 Jan 2:S0002-8703(21)00483-X. doi: 10.1016/j.ahj.2021.12.010.

End-of-life care in the cardiac intensive care unit: a contemporary view from the Critical Care Cardiology Trials Network (CCCTN) Registry. Fagundes A, Berg DD, Bohula EA, Baird-Zars VM, Barnett CF, Carnicelli AP, Chaudhry SP, Guo J, Keeley EC, Kenigsberg BB, Menon V, Miller PE, Newby LK, van Diepen S, Morrow DA, Katz JN. Eur Heart J Acute Cardiovasc Care. 2022 Jan 5:zuab121. doi: 10.1093/ehjacc/zuab121.

Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Bahit MC, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, Fox KA, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Kato ET, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB. Circulation. 2022 Jan 5. doi: 10.1161/CIRCULATIONAHA.121.056355.

Practice Patterns in the Interventional Treatment of Coronary Bifurcation Lesions: A Global Survey. Nikolakopoulos I, Vemmou E, Karacsonyi J, Azzalini L, Bergmark BA, Chatzizisis YS, Hall AB, Wollmuth J, Croce K, Jneid H, Rangan BV, Burke MN, Brilakis ES. J Invasive Cardiol. 2022 Jan;34(1):E43-E48.

Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O’Meara E, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Lindholm D, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJV. JACC Heart Fail. 2022 Jan;10(1):52-64. doi: 10.1016/j.jchf.2021.08.006.

Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Bonaca MP, Antman EM, Cunningham JW, Wiviott SD, Murphy SA, Halperin JL, Weitz JI, Grosso MA, Lanz HJ, Braunwald E, Giugliano RP, Ruff CT. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28:pvab089. doi: 10.1093/ehjcvp/pvab089.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Cardiovasc Comput Tomogr. 2021 Dec 1:S1934-5925(21)00469-X. doi: 10.1016/j.jcct.2021.11.009.

How to implement novel diagnostic algorithms for non-ST-segment elevation myocardial infarction in the emergency department. Cullen L, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Dec 18:zuab118. doi: 10.1093/ehjacc/zuab118.

N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort. O’Donnell C, Ashland MD, Vasti EC, Lu Y, Chang AY, Wang P, Daniels LB, de Lemos JA, Morrow DA, Rodriguez F, O’Brien CG. J Am Heart Assoc. 2021 Dec 10:e022913. doi: 10.1161/JAHA.121.022913.

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Nat Med. 2021 Dec 6. doi: 10.1038/s41591-021-01584-3.

Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJL; DAPA-CKD and DAPA-HF Trial Committees and Investigators. Lancet Diabetes Endocrinol. 2021 Nov 29:S2213-8587(21)00295-3. doi: 10.1016/S2213-8587(21)00295-3.

Exploring patient experiences coping with using multiple medications: a qualitative interview study. Lauffenburger JC, Haff N, McDonnell ME, Solomon DH, Antman EM, Glynn RJ, Choudhry NK. BMJ Open. 2021 Nov 22;11(11):e046860. doi: 10.1136/bmjopen-2020-046860.

Electronic Alerts to Initiate Anticoagulation Dialogue in Patients with Atrial Fibrillation. Antonio Gutierrez J, Ruff CT, Aday AW, Gu L, Schulteis RD, Shihai L, Petrini Pa-C M, Sun AY, Swaminathan RV, Katzenberger DR, Banerjee S, Rao SV. Am Heart J. 2021 Nov 19:S0002-8703(21)00452-X. doi: 10.1016/j.ahj.2021.11.008.

Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel Approach. Proudfoot AG, Kalakoutas A, Meade S, Griffiths MJD, Basir M, Burzotta F, Chih S, Fan E, Haft J, Ibrahim N, Kruit N, Lim HS, Morrow DA, Nakata J, Price S, Rosner C, Roswell R, Samaan MA, Samsky MD, Thiele H, Truesdell AG, van Diepen S, Voeltz MD, Irving PM. Circ Heart Fail. 2021 Nov 22. doi: 10.1161/CIRCHEARTFAILURE.121.008635.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber L. Circ Heart Fail. 2021 Nov 22:CIRCHEARTFAILURE121008837. doi: 10.1161/CIRCHEARTFAILURE.121.008837.

Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). Aoki Y, Hamrén B, Clegg LE, Stahre C, Bhatt DL, Raz I, Scirica BM, Oscarsson J, Carlsson B. PLoS One. 2021 Nov 19;16(11):e0259372. doi: 10.1371/journal.pone.0259372. eCollection 2021.

Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, Filippatos G, Jering K, Landmesser U, Menon V, Prof Merkely B, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Wang Y, Braunwald E. Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.

Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Sabatine MS, Bergmark BA, Murphy SA, O’Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald E. Lancet. 2021 Nov 12:S0140-6736(21)02334-5. doi: 10.1016/S0140-6736(21)02334-5.

The European Heart Journal Acute Cardiovascular Care (EHJ ACVC) 2022: message from the editorial board. Vranckx P, Morrow D, Verbrugge F. Eur Heart J Acute Cardiovasc Care. 2021 Nov 10:zuab101. doi: 10.1093/ehjacc/zuab101.

Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19 : A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Varshney AS, Omar WA, Goodrich EL, Bhatt AS, Wolley AE, Gong J, Senman BC, Silva D, Levangie MW, Berg DD, Yeh RW, de Lemos JA, Morrow DA, Kazi DS, Bohula EA. Circ Heart Fail. 2021 Nov 18: CIRCHEARTFAILURE121008477. doi: 10.1161/CIRCHEARTFAILURE.121.008477.

Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. Rousset A, Dellamonica D, Menuet R, Lira Pineda A, Sabatine MS, Giugliano RP, Trichelair P, Zaslavskiy M, Ricci L.  Eur Heart J. 2021 Nov 15. Doi:10.1093/ehjdz/tab093.

Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT, Sabatine MS. JAMA Cardiol. 2021 Nov 13. doi: 10.1001/jamacardio.2021.5083.

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: Insights from DAPA-HF. Butt JH, Docherty KF, Jhund PS, De Boer RA, Böhm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC, Petrie MC, Ponikowski P, Bengtsson O, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, McMurray JJ, Køber L. Eur J Heart Fail. 2021 Nov 11. doi: 10.1002/ejhf.2381.

Workflow Automation for a Virtual Hypertension Management Program. Gordon WJ, Blood AJ, Chaney K, Clark E, Glynn C, Green R, Laurent JS, Mailly C, McPartlin M, Murphy S, Nichols H, Oates M, Subramaniam S, Varugheese M, Wagholikar K, Aronson S, Scirica BM. Appl Clin Inform. 2021 Oct;12(5):1041-1048. doi: 10.1055/s-0041-1739195. Epub 2021 Nov 10.

Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05795-8. doi: 10.1016/j.jacc.2021.07.053.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Writing Committee Members, Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. J Am Coll Cardiol. 2021 Oct 23:S0735-1097(21)05794-6. doi: 10.1016/j.jacc.2021.07.052.

Cardiogenic Shock After Acute Myocardial Infarction: A Review. Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. JAMA. 2021 Nov 9;326(18):1840-1850. doi: 10.1001/jama.2021.18323.

Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O’Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJV, Sabatine MS, Morrow DA. Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852.

SGLT2 inhibitors: the statins of the 21st century. Braunwald E. Eur Heart J. 2021 Nov 6:ehab765. doi: 10.1093/eurheartj/ehab765.

Interpreting Absolute and Relative Risk Reduction in the Context of Recent Cardiovascular Outcome Trials in Patients with Type 2 Diabetes. Berg DD, Kolkailah AA, Sarraju A, Kerchberger AM, Eljalby M, McGuire DK.
Curr Diab Rep. 2021 Nov 6;21(11):45. doi: 10.1007/s11892-021-01417-0.

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. JAMA Cardiol. 2021 Nov 3. doi: 10.1001/jamacardio.2021.4567.

High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. David D Berg, Marc S Sabatine, Naveed Sattar, Petr Jarolim, Paul WELSH, Pardeep S Jhund, Inder Anand, Rudolf A De Boer, Mikhail Kosiborod, Eileen O’Meara, Ann Hammarstedt, Anna Maria Langkilde, Daniel Lindholm, Mikaela Sjöstrand, John J McMurray, David Morrow. Originally published 8 Nov 2021Circulation. 2021;144:A11692.

Icosapent Ethyl Reduces Ischemic Events in Patients with a History of Prior Coronary Artery Bypass Grafting: REDUCE-IT CABG. Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2021 Oct 28. doi: 10.1161/CIRCULATIONAHA.121.056290.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001030. doi: 10.1161/CIR.0000000000001030.

2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks DB, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O’Connor RE, Ross MA, Shaw LJ. Circulation. 2021 Oct 28:CIR0000000000001029. doi: 10.1161/CIR.0000000000001029.

LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, Falloon J, Hsia J, Guan Y, Conway J, Tsai LF, Hummer BT, Hirshberg B, Kuder J, Murphy SA, George RT, Sabatine MS. Arterioscler Thromb Vasc Biol. 2021 Oct 28:ATVBAHA120315757. doi: 10.1161/ATVBAHA.120.315757.

Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, Gil EG. Respir Res. 2021 Oct 22;22(1):272. doi: 10.1186/s12931-021-01861-2.

Improving prediction of anticoagulant-related major bleeding in atrial fibrillation: The search for new biomarkers. Berg DD, Morrow DA. J Thromb Haemost. 2021 Nov;19(11):2674-2676. doi: 10.1111/jth.15525.

Outcomes of a smartphone-based application with live health-coaching post-percutaneous coronary intervention. Paruchuri K, Finneran P, Marston NA, Healy EW, Andreo J Jr, Lynch R, Blood AJ, Jones-O’Connor M, Lander B, Kelly N, Vivaldi MT, Traynor K, Wiviott S, Natarajan P. EBioMedicine. 2021 Sep 15:103593. doi: 10.1016/j.ebiom.2021.103593.

In Memoriam: A Tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. J Am Coll Cardiol. 2021 Oct 7:S0735-1097(21)07176-X. doi: 10.1016/j.jacc.2021.10.001.

Digital health device measured sleep duration and ideal cardiovascular health: an observational study. Leopold JA, Antman EM. BMC Cardiovasc Disord. 2021 Oct 14;21(1):497. doi: 10.1186/s12872-021-02284-z.

A tribute to Attilio Maseri. Crea F, Braunwald E, Fuster V. Eur Heart J. 2021 Oct 12:ehab714. doi: 10.1093/eurheartj/ehab714.

Cardiac myosin-binding protein C as a biomarker of acute myocardial infarction. Marber MS, Mills NL, Morrow DA, Mueller C. Eur Heart J Acute Cardiovasc Care. 2021 Oct 11:zuab086. doi: 10.1093/ehjacc/zuab086.

Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. Figueroa JM, Lombardo ME, Dogliotti A, Flynn LP, Giugliano R, Simonelli G, Valentini R, Ramos A, Romano P, Marcote M, Michelini A, Salvado A, Sykora E, Kniz C, Kobelinsky M, Salzberg DM, Jerusalinsky D, Uchitel O. Int J Gen Med. 2021 Oct 1;14:6277-6286. doi: 10.2147/IJGM.S328486.

Closing the Gap: Insights into the Epidemiology of Heart Failure Care from the Critical Care Cardiology Trials Network. Morrow DA. J Card Fail. 2021 Oct;27(10):1146-1147.

De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry. Bhatt AS, Berg DD, Bohula EA, Alviar CL, Baird-Zars VM, Barnett CF, Burke JA, Carnicelli AP, Chaudhry SP, Daniels LB, Fang JC, Fordyce CB, Gerber DA, Guo J, Jentzer JC, Katz JN, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Nativi-Nicolau J, Phreaner N, Roswell RO, Sinha SS, Jeffrey Snell R, Solomon MA, Van Diepen S, Morrow DA. J Card Fail. 2021 Oct;27(10):1073-1081.

The Nexus of Heart Failure and Critical Care Cardiology. Sinha SS, Bohula EA, Katz JN. J Card Fail. 2021 Oct;27(10):1041.

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. Gilchrist IC Jr, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. J Am Heart Assoc. 2021 Oct 8:e021412.

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Gaba P, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Tardif JC, Ballantyne CM, Pinto DS, Budoff MJ, Gibson CM.J Am Coll Cardiol. 2021 Oct 12;78(15):1525-1537.

Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald E. J Am Coll Cardiol. 2021 Oct 12;78(15):1499-1507.

Heart failure with preserved ejection fraction: a stepchild no more! Braunwald E. Eur Heart J. 2021 Oct 7;42(38):3900-3901.

Risk factors for type 2 MI: the usual suspects or guilt by association? O’Donoghue ML, Marston NA. Eur Heart J. 2021 Oct 2:ehab707. doi: 10.1093/eurheartj/ehab707.

Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL; VANISH Investigators, Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Nat Med. 2021 Sep 23. doi: 10.1038/s41591-021-01505-4.

Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams. Papolos AI, Kenigsberg BB, Berg DD, Alviar CL, Bohula E, Burke JA, Carnicelli AP, Chaudhry SP, Drakos S, Gerber DA, Guo J, Horowitz JM, Katz JN, Keeley EC, Metkus TS, Nativi-Nicolau J, Snell JR, Sinha SS, Tymchak WJ, Van Diepen S, Morrow DA, Barnett CF; Critical Care Cardiology Trials Network Investigators. J Am Coll Cardiol. 2021 Sep 28;78(13):1309-1317. doi: 10.1016/j.jacc.2021.07.044.

Walking the tightrope between ischaemia and bleeding. O’Donoghue ML, Patel SM. EuroIntervention. 2021 Sep 20;17(7):527-529. doi: 10.4244/EIJV17I7A93.

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DA. Diabetes Care. 2021 Sep 17:dc211170. doi: 10.2337/dc21-1170.

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Chuecos F, Garcia Gil E, Chapman KR. Adv Ther. 2021 Sep 15. doi: 10.1007/s12325-021-01878-5.

Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Kazuma Oyama, Robert P Giugliano, Minao Tang, Marc P Bonaca, Jeffrey L Saver, Sabina A Murphy, Andrea Ruzza, Anthony C Keech, Peter S Sever, Marc S Sabatine, Brian A Bergmark. Eur Heart J. 2021 Sept 19; ehab604. doi: 10.1093/eurheartj/ehab604.

Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction – Findings from the LATITUDE TIMI 60 Trial. Cavender MA, O’Donoghue M, Abbate A, Aylward P, Fox KAA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DA. Am Heart J. 2021 Sep 8:S0002-8703(21)00229-5. doi: 10.1016/j.ahj.2021.08.022.

Population Health Identification and Management of Low Density Lipoprotein Cholesterol via a Remote, Algorithmic, Navigator-Executed Program. Plutzky J, Benson MD, Chaney K, Bui TV, Kraft M, Matta L, McPartlin M, Zelle D, Cannon CP, Dodek A, Gaziano TA, Desai AS, MacRae CA, Scirica BM. Am Heart J. 2021 Sep 2:S0002-8703(21)00223-4. doi: 10.1016/j.ahj.2021.08.017.

The genomics of heart failure: design and rationale of the HERMES consortium. Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O’Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F; Regeneron Genetics Center, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JG. ESC Heart Fail. 2021 Sep 3. doi: 10.1002/ehf2.13517.

Cardiovascular Benefit of Lowering LDL Cholesterol Below 40 mg/dl. Marston NA, Giugliano RP, Park JG, Ruzza A, Sever PS, Keech AC, Sabatine MS. Circulation. 2021 Aug 27. doi: 10.1161/CIRCULATIONAHA.121.056536.

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV. Eur Heart J. 2021 Aug 27:ehab560. doi: 10.1093/eurheartj/ehab560.

A new initiative of the European Heart Journal: the Desmond Julian Award. Crea F, Braunwald E. Eur Heart J. 2021 Aug 26:ehab535. doi: 10.1093/eurheartj/ehab535.

Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. Marcusa DP, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Aug 25. doi: 10.1001/jamacardio.2021.3028.

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SD. Eur Heart J. 2021 Aug 24:ehab530. doi: 10.1093/eurheartj/ehab530.

Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Aug 21:e020446. doi: 10.1161/JAHA.120.020446.

Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. Giugliano RP, Gencer B, Wiviott SD, Park JG, Fuchs CS, Goessling W, Musliner TA, Tershakovec AM, Blazing MA, Califf R, Cannon CP, Braunwald E. JACC CardioOncol. 2020 Sep 15;2(3):385-396. doi: 10.1016/j.jaccao.2020.07.008. eCollection 2020 Sep.

Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives. Cho L, Vest AR, O’Donoghue ML, Ogunniyi MO, Sarma AA, Denby KJ, Lau ES, Poole JE, Lindley KJ, Mehran R; Cardiovascular Disease in Women Committee Leadership Council. J Am Coll Cardiol. 2021 Aug 17;78(7):737-751.

An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience. Antman EM, Freeman MW, Golan DE, Kitterman R, McKenna E, Parrish J, Vaughan C, Watts L, Loscalzo J. J Clin Transl Sci. 2021 May 17;5(1):e137.

Transmethylamine-N-Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. Colaco NA, Wang TS, Ma Y, Scherzer R, Ilkayeva OR, Desvigne-Nickens P, Braunwald E, Hernandez AF, Butler J, Shah SH, Shah SJ, Hsue PY. J Am Heart Assoc. 2021 Aug 7:e020499. doi: 10.1161/JAHA.120.020499.

A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. Berg DD, Giugliano RP, Ruff CT, Tang M, Im K, Jarolim P, Rutman H, Antman EM, Braunwald E, Morrow DA. J Am Coll Cardiol. 2021 Aug 10;78(6):634-636. doi: 10.1016/j.jacc.2021.06.008.

How to live to 100 before developing clinical coronary artery disease: a suggestion. Braunwald E. Eur Heart J. 2021 Aug 6:ehab532. doi: 10.1093/eurheartj/ehab532.

Cholesterol: the race to the bottom. Braunwald E. Eur Heart J. 2021 Aug 2:ehab446. doi: 10.1093/eurheartj/ehab446.

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees. JAMA Cardiol. 2021 Jul 28. doi: 10.1001/jamacardio.2021.2632.

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O’Donoghue ML. Eur J Prev Cardiol. 2021 Jul 23;28(8):805-812.

A precision medicine approach to sex-based differences in ideal cardiovascular health. Leopold JA, Antman EM. Sci Rep. 2021 Jul 21;11(1):14848.

Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DA. Circulation. 2021 Jul 20;144(3):249-251.

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang CE, Diez M, Drożdż J, Dukát A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJ. Eur J Heart Fail. 2021 Jul 16. doi: 10.1002/ejhf.2308.

Early Aspirin Use, Allograft Rejection, and Cardiac Allograft Vasculopathy in Heart Transplantation. Bergmark BA, Zelniker TA, Kim M, Mehra MR, Stewart GC, Page DS, Woodcome EL, Givertz MM. Clin Transplant. 2021 Jul 13. doi: 10.1111/ctr.14424. 

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. Diabetes Care. 2021 Jul 7:dc210076. doi: 10.2337/dc21-0076.

Ideal Cardiovascular Health in Former Smokers. Leopold JA, Antman EM. J Clin Med. 2021 Jun 1;10(11):2450. doi: 10.3390/jcm10112450.

Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? Steffel J, Ruff CT, Antman EM, Braunwald E, Giugliano RP. J Am Coll Cardiol. 2021 Jun 29;77(25):3232-3233.

Myocardial Infarction and Evolocumab-Reply. Wiviott SD, Giugliano RP, Sabatine MS. JAMA Cardiol. 2021 Jun 23. doi: 10.1001/jamacardio.2021.2000

Reflections on Hypertrophic Cardiomyopathy. Braunwald E. Eur Heart J. 2021 Jun 21:ehab337. doi: 10.1093/eurheartj/ehab337.

Platelet Reactivity and Coagulation Markers in Patients with COVID-19. Bertolin AJ, Dalçóquio TF, Salsoso R, de M Furtado RH, Kalil-Filho R, Hajjar LA, Siciliano RF, Kallás EG, Baracioli LM, Lima FG, Giraldez RR, Cavalheiro-Filho C, Vieira A, Strunz CMC, Giugliano RP, Tantry US, Gurbel PA, Nicolau JC. Adv Ther. 2021 Jun 4. doi: 10.1007/s12325-021-01803-w.

Hypertensive Heartbreak. Lau ES, Scirica B, Schaefer IM, Miller AL, Loscalzo J. N Engl J Med. 2021 Jun 3;384(22):2145-2152. doi: 10.1056/NEJMcps2018493.

Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. Marc S. Sabatine MD, MPH Eugene Braunwald MD. Journal of the American College of Cardiology. Volume 77, Issue 22, 8 June 2021, Pages 2822-2845.

Hypertensive Heartbreak. Lau ES, Vaidya A, Schaefer IM, Scirica BM. N Engl J Med. 2021 May 27;384(21):e80. doi: 10.1056/NEJMimc2031595.

Transseptal left heart catheterization: birth, death, and resurrection. Braunwald E. Eur Heart J. 2021 May 25:ehab264. doi: 10.1093/eurheartj/ehab264.

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects – A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.  Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MS; FOURIER Study Group. Circ J. 2021 May 12. doi: 10.1253/circj.CJ-20-1051.

Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic. Roth GA, Emmons-Bell S, Alger HM, Bradley SM, Das SR, de Lemos JA, Gakidou E, Elkind MSV, Hay S, Hall JL, Johnson CO, Morrow DA, Rodriguez F, Rutan C, Shakil S, Sorensen R, Stevens L, Wang TY, Walchok J, Williams J, Murray C. JAMA Netw Open. 2021 May 3;4(5):e218828. doi: 10.1001/jamanetworkopen.2021.8828.

Initial Findings From the North American COVID-19 Myocardial Infarction Registry. Garcia S, Dehghani P, Grines C, Davidson L, Nayak KR, Saw J, Waksman R, Blair J, Akshay B, Garberich R, Schmidt C, Ly HQ, Sharkey S, Mercado N, Alfonso CE, Misumida N, Acharya D, Madan M, Hafiz AM, Javed N, Shavadia J, Stone J, Alraies MC, Htun W, Downey W, Bergmark BA, Ebinger J, Alyousef T, Khalili H, Hwang CW, Purow J, Llanos A, McGrath B, Tannenbaum M, Resar J, Bagur R, Cox-Alomar P, Stefanescu Schmidt AC, Cilia LA, Jaffer FA, Gharacholou M, Salinger M, Case B, Kabour A, Dai X, Elkhateeb O, Kobayashi T, Kim HH, Roumia M, Aguirre FV, Rade J, Chong AY, Hall HM, Amlani S, Bagherli A, Patel RAG, Wood DA, Welt FG, Giri J, Mahmud E, Henry TD; Society for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. J Am Coll Cardiol. 2021 Apr 27;77(16):1994-2003. doi: 10.1016/j.jacc.2021.02.055.

Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DA. J Am Heart Assoc. 2021 Apr 22:e018673. doi: 10.1161/JAHA.120.018673.

Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science. Sabatine MS. JAMA Cardiol. 2021 Apr 21. doi: 10.1001/jamacardio.2021.0693.

The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry. Lawler PR, Berg DD, Park JG, Katz JN, Baird-Zars VM, Barsness GW, Bohula EA, Carnicelli AP, Chaudhry SP, Jentzer JC, Menon V, Metkus T, Nativi-Nicolau J, Phreaner N, Sinha SS, Teuteberg JJ, van Diepen S, Morrow DA; Critical Care Cardiology Trials Network Investigators. Crit Care Med. 2021 Apr 2. doi: 10.1097/CCM.0000000000004948.

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. JAMA Cardiol. 2021 Apr 14. doi: 10.1001/jamacardio.2021.0660.

Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, Maggioni AP, Mann D, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, van der Meer P, Wernsing M, Carter K, Guo W, Zhou Y, Lefkowitz M, Gong J, Wang Y, Merkely B, Macin SM, Shah U, Nicolau JC, Braunwald E. Eur J Heart Fail. 2021 Apr 12. doi: 10.1002/ejhf.2191.

Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, Mozaffarian D, Sabatine MS, O’Donoghue ML. J Am Heart Assoc. 2021 Apr 12:e017401. doi: 10.1161/JAHA.120.017401.

Nonprofit Advocacy at the American Heart Association: Creating a Visionary Way Forward at Our 40th Anniversary: An American Heart Association Policy Statement. Churchwell K, Antman E, Birnbaum J, Desai NR, Harrington RA, Holubowich EJ, Ivy KN, Schoeberl M, Warner JJ, White CJ, Whitsel LP, Yancy C; American Heart Association Advocacy Coordinating Committee. Circulation. 2021 Apr 12:CIR0000000000000972. doi: 10.1161/CIR.0000000000000972.

Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial. Cavallari I, Bhatt DL, Steg PG, Leiter LA, McGuire DK, Mosenzon O, Im K, Raz I, Braunwald E, Scirica BM. J Am Coll Cardiol. 2021 Apr 13;77(14):1837-1840. doi: 10.1016/j.jacc.2021.02.030.

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF. Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJV. Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.

Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice. Smith KV, Dunning JR, Fischer CM, MacLean TE, Bosque-Hamilton JW, Fera LE, Grant JY, Zelle DJ, Matta L, Gaziano TA, MacRae CA, Scirica BM, Desai AS. J Pharm Pract. 2021 Apr 5:8971900211004840. doi: 10.1177/08971900211004840.

Data from Digital Health Devices Informs Ideal Cardiovascular Health. Leopold JA, Davis RB, Antman EM. J Pers Med. 2021 Mar 10;11(3):189. doi: 10.3390/jpm11030189.

Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjöstrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Køber L. JAMA Cardiol. 2021 Mar 31. doi: 10.1001/jamacardio.2021.0379.

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. Wise RA, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D, Garcia-Gil E. Int J Chron Obstruct Pulmon Dis. 2021 Mar 18;16:689-699. doi: 10.2147/COPD.S285068.

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, Colan SD, Rossano JW, Wittekind SG, Ware JS, Saberi S, Helms AS, Ho CY. Eur Heart J. 2021 Mar 26:ehab148. doi: 10.1093/eurheartj/ehab148.

Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, Murphy SA, Lanz HJ, Grosso MA, Antman EM, Braunwald E, Morrow DA. Eur Heart J. 2021 Mar 24:ehab141. doi: 10.1093/eurheartj/ehab141.

SPOT the DIAGNOSIS. Verbrugge FH, Morrow DA, Vranckx P. Eur Heart J Acute Cardiovasc Care. 2021 Mar 24:zuab011. doi: 10.1093/ehjacc/zuab011.

Trends in Therapy and Outcomes Associated With Respiratory Failure in Patients Admitted to the Cardiac Intensive Care Unit. Jentzer JC, Alviar CL, Miller PE, Metkus T, Bennett CE, Morrow DA, Barsness GW, Kashani KB, Gajic O. J Intensive Care Med. 2021 Mar 24:8850666211003489. doi: 10.1177/08850666211003489.

Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. Ravvaz K, Weissert JA, Jahangir A, Ruff CT. PLoS One. 2021 Mar 18;16(3):e0248134. doi: 10.1371/journal.pone.0248134. eCollection 2021.

The Birth of Cardiology: The Golden Decade. Braunwald E. Eur Heart J. 2021 Mar 10:ehab119. doi: 10.1093/eurheartj/ehab119.

Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Steffel J, Ruff CT, Yin O, Braunwald E, Park JG, Murphy SA, Connolly S, Antman EM, Giugliano RP. J Am Coll Cardiol. 2021 Mar 9;77(9):1197-1207.

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SD. Diabetes Care. 2021 Mar 2:dc202492. doi: 10.2337/dc20-2492.

Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”. Giugliano RP, De Caterina R, Yamashita T. Drug Saf. 2021 Feb 24. doi: 10.1007/s40264-021-01055-1.

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, O’Donoghue ML. Eur J Prev Cardiol. 2020 Dec 29:zwaa143. doi: 10.1093/eurjpc/zwaa143.

Effect of dapagliflozin on anaemia in DAPA-HF. Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Eur J Heart Fail. 2021 Feb 22. doi: 10.1002/ejhf.2132.

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. O’Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SD. Diabetologia. 2021 Feb 20. doi: 10.1007/s00125-021-05399-2.

Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction. Metkus T, Miller PE, Alviar CL, Jentzer JC, van Diepen S, Katz JN, Morrow DA, Schulman S, Eid S. Eur Heart J Acute Cardiovasc Care. 2020 Apr 23:2048872620919947. doi: 10.1177/2048872620919947.

Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20:2048872619896205. doi: 10.1177/2048872619896205.

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: results from the DEFINE-HF Trial. Nassif ME, Windsor SL, Tang F, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Fong MW, LaRue SJ, Umpierrez G, Hartupee J, Khariton Y, Malik AO, Ogunniyi MO, Wenger NK, Kosiborod MN. Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14352.

The Path to Universality. Braunwald E, Antman EM. Eur J Heart Fail. 2021 Feb 18. doi: 10.1002/ejhf.2129.

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease. Patel PN, Giugliano RP. Glob Cardiol Sci Pract. 2020 Dec 31;2020(3):e202039. doi: 10.21542/gcsp.2020.39.

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MS. JAMA Cardiol. 2021 Feb 17. doi: 10.1001/jamacardio.2020.7585.

Efficacy and Safety of Dapagliflozin According to Aetiology in Heart Failure with Reduced Ejection Fraction: Insights from the DAPA-HF trial. Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Bengtsson O, Jhund PS, McMurray JJV, Køber L. Eur J Heart Fail. 2021 Feb 16. doi: 10.1002/ejhf.2124.

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Zelniker TA, Ardissino M, Andreotti F, O’Donoghue ML, Yin O, Park JG, Murphy SA, Ruff CT, Lanz HJ, Antman EM, Braunwald E, Giugliano RP, Merlini PA. Circulation. 2021 Feb 16;143(7):673-684. doi: 10.1161/CIRCULATIONAHA.120.052216.

Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O’Donoghue ML. Circulation. 2021 Feb 16;143(7):685-695. doi: 10.1161/CIRCULATIONAHA.120.052339. 

Potential growth in cardiogenic shock research though an international registry collaboration: the merits and challenges of a Hub-of-Spokes model. van Diepen S, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2021 Jan 4:zuaa038. doi: 10.1093/ehjacc/zuaa038.

Learning and innovation among interventional cardiologists: Insights from an international survey. Vemmou E, Nikolakopoulos I, Xenogiannis I, Karacsonyi J, Rangan BV, Garcia S, Burke MN, Jneid H, Croce KJ, Bergmark BA, Brilakis ES. Catheter Cardiovasc Interv. 2021 Feb 10. doi: 10.1002/ccd.29548.

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. J Am Heart Assoc. 2021 Feb 9:e017008. doi: 10.1161/JAHA.120.017008.

Comprehensive characterization of protein-protein interactions perturbed by disease mutations. Cheng F, Zhao J, Wang Y, Lu W, Liu Z, Zhou Y, Martin WR, Wang R, Huang J, Hao T, Yue H, Ma J, Hou Y, Castrillon JA, Fang J, Lathia JD, Keri RA, Lightstone FC, Antman EM, Rabadan R, Hill DE, Eng C, Vidal M, Loscalzo J. Nat Genet. 2021 Feb 8. doi: 10.1038/s41588-020-00774-y.

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O’Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV. JACC Heart Fail. 2021 Jan 28:S2213-1779(20)30704-6. doi: 10.1016/j.jchf.2020.11.009.

Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Circ Heart Fail. 2021 Feb 3:CIRCHEARTFAILURE120007034. doi: 10.1161/CIRCHEARTFAILURE.120.007034.

Cardiology in 2021. Braunwald E. Eur Heart J. 2021 Feb 2:ehab025. doi: 10.1093/eurheartj/ehab025.

Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PG; TAO investigators. Arch Cardiovasc Dis. 2021 Jan 28:S1875-2136(21)00004-8. doi: 10.1016/j.acvd.2020.09.005.

Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment. Ting C, Rhoten M, Dempsey J, Nichols H, Fanikos J, Ruff CT. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620987900. doi: 10.1177/1076029620987900.

Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study. de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, Grip L, Lanz H, Mercuri MF, Antman EM, Giugliano R. Am Heart J. 2021 Jan 22:S0002-8703(21)00017-X. doi: 10.1016/j.ahj.2021.01.013.

Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design. Bonaca MP, George RT, Morrow DA, Bergmark BA, Park JG, Abuhatzira L, Vavere AL, Karathanasis SK, Jin C, She D, Hirshberg B, Hsia J, Sabatine MS. Eur Heart J Cardiovasc Pharmacother. 2021 Jan 25:pvab001. doi: 10.1093/ehjcvp/pvab001.

Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Baris Gencer, David A Morrow, Eugene Braunwald, Erica L Goodrich, Mika Hilvo, Dimple Kauhanen, Marc S Sabatine, Reijo Laaksonen, Michelle L O’Donoghue. European Journal of Preventive Cardiology, https://doi.org/10.1093/eurjpc/zwaa143. Published: 29 December 2020.

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Nelson SE, Giugliano RP, Antman EM, Park JG, Norden AD, Rost NS, Silverman S, Singhal AB, Lanz HJ, Braunwald E, Ruff CT; ENGAGE AF-TIMI 48 Steering Committee and Investigators. J Clin Neurosci. 2021 Jan 11:S0967-5868(20)31595-2. doi: 10.1016/j.jocn.2020.10.036.

Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Circ G enom Precis Med. 2021 Jan 12. doi: 10.1161/CIRCGEN.120.003006.

Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C Jr, Petrauskiene B, Henry P, Dorobantu M, French WJ, Wiviott SD, Sabatine MS, Mehta SR, Steg PG. Circ Cardiovasc Interv. 2021 Jan 12:CIRCINTERVENTIONS120009759. doi: 10.1161/CIRCINTERVENTIONS.120.009759.

Letter to the editor re: ‘serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review’. Sabatine MS, Giugliano RP, Schwartz GG. Expert Rev Clin Pharmacol. 2021 Jan 12:1-2. doi: 10.1080/17512433.2021.1874346.

Cardiac troponin elevation after elective PCI: adding infarct to major injury. Bergmark BA, Morrow DA. Eur  Heart J. 2021 Jan 7:ehaa983. doi: 10.1093/eurheartj/ehaa983.

Effects of dapagliflozin in heart failure with reduced ejection fraction, and COPD: An analysis of DAPA-HF. Dewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Verma S, Jhund PS, McMurray JJ. Eur J Heart Fail. 2020 Dec 23. doi: 10.1002/ejhf.2083.

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Bělohlávek J, Böhm M, Chiang CE, de Boer RA, Diez M, Dukát A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjöstrand M, Jhund PS, McMurray JJV; DAPA-HF Investigators and Committees. Diabetes Care. 2020 Dec 18:dc201675. doi: 10.2337/dc20-1675.

Biomarkers for Risk Assessment in Atrial Fibrillation. Berg DD, Ruff CT, Morrow DA. Clin Chem. 2020 Dec 13:hvaa298. doi: 10.1093/clinchem/hvaa298.

Beyond the ISCHEMIA Trial: Revascularization for Stable Ischemic Heart Disease in Patients With High‐Risk Coronary Anatomical Features. Brian A. Bergmark, and David A. Morrow. Journal of the American Heart Association. Originally published 19 Dec 2020. doi.org/10.1161/JAHA.120.019974.

Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A COllaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant usE in Atrial Fibrillation) Investigators. Carnicelli AP, Hong H, Giugliano RP, Connolly SJ, Eikelboom J, Patel MR, Wallentin L, Morrow DA, Wojdyla D, Hua K, Hohnloser SH, Oldgren J, Ruff CT, Piccini JP, Lopes RD, Alexander JH, Granger CB, On Behalf Of The Combine Af Investigators. Am Heart J. 2020 Dec 6:S0002-8703(20)30401-4. doi: 10.1016/j.ahj.2020.12.002.

New clues for optimal diagnosis and treatment of an old foe: the acute aortic syndrome. Bonaca MP, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2020 Oct;9(3_suppl):S1-S2. doi: 10.1177/2048872620976508.

Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting. O’Donoghue ML, Sabatine MS. Eur Heart J. 2020 Dec 7:ehaa741. doi: 10.1093/eurheartj/ehaa741.

Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58. Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Bode C, Lewis BS, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Wiviott SD. Eur J Heart Fail. 2020 Dec 2. doi: 10.1002/ejhf.2073. 

Advanced Respiratory Support in the Contemporary Cardiac ICU. Metkus TS, Miller PE, Alviar CL, Baird-Zars VM, Bohula EA, Cremer PC, Gerber DA, Jentzer JC, Keeley EC, Kontos MC, Menon V, Park JG, Roswell RO, Schulman SP, Solomon MA, van Diepen S, Katz JN, Morrow DA. Crit Care Explor. 2020 Sep 17;2(9):e0182. doi: 10.1097/CCE.0000000000000182. eCollection 2020 Sep.

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. Piazza G, Morrow DA. JAMA. 2020 Nov 23. doi: 10.1001/jama.2020.23422.

NT-proBNP: Can We Better Utilize Biomarkers in Patients With Diabetes? Cavender MA, Scirica BM. Diabetes Care. 2020 Dec;43(12):2904-2905. doi: 10.2337/dci20-0047.

Which patients with acute coronary syndrome need the cardiac intensive care unit: tuning the tools for risk stratification. De Paiva Fagundes A, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2020 Sep;9(6):543-545. doi: 10.1177/2048872620963490.

Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. Scirica BM, Cannon CP, Fisher NDL, Gaziano TA, Zelle D, Chaney K, Miller A, Nichols H, Matta L, Gordon WJ, Murphy S, Wagholikar KB, Plutzky J, MacRae CA. Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.051913.

Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry. Rodriguez F, Solomon N, de Lemos JA, Das SR, Morrow DA, Bradley SM, Elkind MSV, Williams Iv JH, Holmes D, Matsouaka RA, Gupta D, Gluckman TJ, Abdalla M, Albert MA, Yancy CW, Wang TY. Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.052278.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030186.

PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply. Bergmark BA, Sabatine MS. JAMA Cardiol. 2020 Nov 11. doi: 10.1001/jamacardio.2020.5613.

Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Yeoh SE, Dewan P, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Sjöstrand M, Langkilde AM, McMurray JJ. Circ Heart Fail. 2020 Nov 9. doi: 10.1161/CIRCHEARTFAILURE.120.007879.

Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Nicholas A. Marston, Parth N. Patel, Frederick K. Kamanu, Francesco Nordio, Giorgio M. Melloni, Carolina Roselli, Yared Gurmu, Lu-Chen Weng, Marc P. Bonaca, Robert P. Giugliano, Benjamin M. Scirica, Michelle L. O’Donoghue, Christopher P. Cannon, Christopher D. Anderson, Deepak L. Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F. Storey, Peter Sever, Anthony C Keech, Itamar Raz, Ofri Mosenzon, Elliott M. Antman, Eugene Braunwald, Patrick T. Ellinor, Steven A. Lubitz, Marc S. Sabatine, and Christian T. Ruff. Circulation. 13 Nov 2020. Doi:10.1161/CIRCULATIONAHA.120.051927.

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. Daniel P. Marcusa, MD, Robert P. Giugliano, MD, Jeong-Gun Park, PhD, James A. de Lemos, MD, Christopher P. Cannon, MD, Marc S. Sabatine, MD, MPH. JAMA Cardiol. Published online November 13, 2020. doi:10.1001/jamacardio.2020.6184.

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Kazuma Oyama, Remo H.M. Furtado, Antonio Fagundes, Thomas A. Zelniker, Minao Tang, Julia Kuder, Sabina A. Murphy, Andrew Hamer, Huei Wang, Anthony C. Keech, Robert P. Giugliano, Marc S. Sabatine, and Brian A. Bergmark. J Am Coll Cardiol. Nov 13, 2020. Epublished DOI: 10.1016/j.jacc.2020.11.011.

Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Baris Gencer, MD, Nicholas A Marston, MD, KyungAh Im, PhD, Christopher P Cannon, MD, Peter Sever, FRCP, Anthony Keech, MD, Eugene Braunwald, MD, Robert P. Giugliano, MD, Marc S. Sabatine, MD. The Lancet. November 10, 2020. DOI:10.1016/S0140-6736(20)32332-1.

Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT Jr, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif JC, Verma S, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2020 Nov 5. doi: 10.1161/CIRCULATIONAHA.120.050276.

Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Vilain K, Li H, Kwong WJ, Antman EM, Ruff CT, Braunwald E, Cohen DJ, Giugliano RP, Magnuson EA; ENGAGE AF-TIMI 48 Trial Investigators. Circ Cardiovasc Qual Outcomes. 2020 Nov 5:CIRCOUTCOMES120006511. doi: 10.1161/CIRCOUTCOMES.120.006511.

Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. Gorski M, …O’Donoghue ML et al. Kidney Int. 2020 Oct 30:S0085-2538(20)31239-4. doi: 10.1016/j.kint.2020.09.030. 

A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the COVID-19 Pandemic. Fader KA, Zhang J, Menetski JP, Thadhani RI, Antman EM, Friedman GS, Ramaiah SK, Vaidya VS. J Pharmacol Exp Ther. 2020 Oct 28:JPET-MR-2020-000204. doi: 10.1124/jpet.120.000204.

Prevention of Complications in the Cardiac Intensive Care Unit: A Scientific Statement From the American Heart Association. Fordyce CB, Katz JN, Alviar CL, Arslanian-Engoren C, Bohula EA, Geller BJ, Hollenberg SM, Jentzer JC, Sims DB, Washam JB, van Diepen S; American Heart Association Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Stroke Council. Circulation. 2020 Oct 29:CIR0000000000000909. doi: 10.1161/CIR.0000000000000909.

In Reply to Dyster and Penner. Divakaran S, Berg DD, Warner LN, Stern RM. Acad Med. 2020 Nov;95(11):1626-1627. doi: 10.1097/ACM.0000000000003671.

Response by Marston et al to Letter Regarding Article, “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism”. Marston NA, Ruff CT, Sabatine MS. Circulation. 2020 Oct 27;142(17):e264. doi: 10.1161/CIRCULATIONAHA.120.050174. Epub 2020 Oct 26.

Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. van Diepen S, Tymchak W, Bohua EA, Park J-G, Daniels LB, Phreaner N, Barnett CF, Kenigsberg BB, De Filippis A, Singam NS, Barsness GW, Jentzer JC, Ternus B, Morrow DA, Katz JN, Critical Care Cardiology Trials Network Investigators. Am Heart J. 2020 Apr;222:8-14. doi: 10.1016/j.ahj.2020.01.005.

Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. Xu H, Yang Y, Wang C, Yang J, Li W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan X, Gao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SD; China Acute Myocardial Infarction Registry Investigators. JAMA Netw Open. 2020 Oct 1;3(10):e2021677. doi: 10.1001/jamanetworkopen.2020.21677.

Practice pattern of use of high sensitivity troponin in the outpatient settings. Ferro EG, Bhatt AS, Zhou G, Fiumara K, Wasfy JH, Sequist TD, Morrow DA, Scirica BM. Clin Cardiol. 2020 Oct 22. doi: 10.1002/clc.23482.

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJV; DAPA-HF Investigators and Committees.
Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402.

Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV Jr, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG; TAO investigators. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20:2048872619896205. doi: 10.1177/2048872619896205.

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF. Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkely B, O’Meara E, Schou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV. Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.

Left Ventricular Unloading is Associated with Lower Mortality in Cardiogenic Shock Patients Treated with Veno-Arterial Extracorporeal Membrane Oxygenation: Results From An International, Multicenter Cohort Study. Schrage B, Becher PM, Bernhardt A, Bezerra H, Blankenberg S, Brunner S, Colson P, Cudemus Deseda G, Dabboura S, Eckner D, Eden M, Eitel I, Frank D, Frey N, Funamoto M, Goßling A, Graf T, Hagl C, Kirchhof P, Kupka D, Landmesser U, Lipinski J, Lopes M, Majunke N, Maniuc O, McGrath D, Möbius-Winkler S, Morrow DA, Mourad M, Noel C, Nordbeck P, Orban M, Pappalardo F, Patel SM, Pauschinger M, Pazzanese V, Reichenspurner H, Sandri M, Schulze PC, Schwinger RHG, Sinning JM, Aksoy A, Skurk C, Szczanowicz L, Thiele H, Tietz F, Varshney A, Wechsler L, Westermann D. Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.048792.

Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. Samsky MD, Krucoff MW, Morrow DA, Abraham WT, Aguel F, Althouse AD, Chen E, Cigarroa JE, DeVore AD, Farb A, Gilchrist IC, Henry TD, Hochman JH, Kapur NK, Morrow V, Ohman EM, O’Neill WW, Piña IL, Proudfoot AG, Sapirstein JS, Seltzer JH, Senatore F, Shinnar M, Simonton CA, Tehrani BN, Thiele H, Truesdell AG, Waksman R, Rao SV. Am Heart J. 2020 Oct 1:S0002-8703(20)30271-4. doi: 10.1016/j.ahj.2020.09.015.

Reply to: COVID-19 Related Respiratory Failure and Lymphopenia Do Not Seem Associated with Pneumocystosis. Menon AA, Berg DD, Gay EB, Fredenburgh LE; all the authors of “A Case of COVID-19 and Pneumocystis jirovecii Co-infection”. Am J Respir Crit Care Med. 2020 Sep 17. doi: 10.1164/rccm.202008-3174LE.

Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. Desai AS, Maclean T, Blood AJ, Bosque-Hamilton J, Dunning J, Fischer C, Fera L, Smith KV, Wagholikar K, Zelle D, Gaziano T, Plutzky J, Scirica B, MacRae CA. JAMA Cardiol. 2020 Sep 16. doi: 10.1001/jamacardio.2020.3757.

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP. Thromb Haemost. 2020 Sep 13. doi: 10.1055/s-0040-1716540.

Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O’Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD; PIONEER-HF Investigators. JACC Heart Fail. 2020 Sep 4:S2213-1779(20)30452-2. doi: 10.1016/j.jchf.2020.06.019.

Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial”. Zelniker TA, Raz I, Sabatine MS, Wiviott SD. Circulation. 2020 Sep 8;142(10):e129-e130. doi: 10.1161/CIRCULATIONAHA.120.049841. Epub 2020 Sep 8. 

Effect of Dapagliflozin on Outpatient Worsening of Patients with Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau JC, O’Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJV. Circulation. 2020 Sep 4. doi: 10.1161/CIRCULATIONAHA.120.047480.

Invasive or Conservative Strategy for Stable Coronary Disease. Reply. Antman EM, Braunwald E. N Engl J Med. 2020 Sep 3;383(10):e66. doi: 10.1056/NEJMc2024008.

Contemporary Management of Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome: JACC Council Perspectives. Jentzer JC, Bihorac A, Brusca SB, Del Rio-Pertuz G, Kashani K, Kazory A, Kellum JA, Mao M, Moriyama B, Morrow DA, Patel HN, Rali AS, van Diepen S, Solomon MA; Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council. J Am Coll Cardiol. 2020 Sep 1;76(9):1084-1101. doi: 10.1016/j.jacc.2020.06.070.

Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ; PIONEER-HF Investigators. J Am Coll Cardiol. 2020 Sep 1;76(9):1034-1048.

Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents -Post-hoc Analyses from DECLARE-TIMI 58. Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I. Diabetes Obes Metab. 2020 Aug 26. doi: 10.1111/dom.14179.

Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. McCarthy CP, Murphy S, Jones-O’Connor M, Olshan DS, Khambhati JR, Rehman S, Cadigan JB, Cui J, Meyerowitz EA, Philippides G, Friedman LS, Kadar AY, Hibbert K, Natarajan P, Massaro AF, Bohula EA, Morrow DA, Woolley AE, Januzzi JL Jr, Wasfy JH. EClinicalMedicine. 2020 Aug 19:100504. doi: 10.1016/j.eclinm.2020.100504.

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJV. Eur Heart J. 2020 Aug 21:ehaa496. doi: 10.1093/eurheartj/ehaa496.

Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA. JACC Heart Fail. 2020 Aug 7:S2213-1779(20)30384-X. doi: 10.1016/j.jchf.2020.06.008.

Dapagliflozin and Cardiac, Kidney and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, Furtado RHM, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MS. Circulation. 2020 Aug 3. doi: 10.1161/CIRCULATIONAHA.119.044775.

Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay’s Limit of Detection? Wu AHB, Kavsak PA, Aakre KM, Christenson RH, Apple FS, Peacock WF, Hollander JE, de Lemos JA, Morrow D, Januzzi J, Jaffe AS. Clin Chem. 2020 Aug 12:hvaa160. doi: 10.1093/clinchem/hvaa160.

Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. JAMA Cardiol. 2020 Aug 12. doi: 10.1001/jamacardio.2020.2822.

Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. JAMA Cardiol. 2020 Aug 12. doi: 10.1001/jamacardio.2020.3151.

Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. JAMA Cardiol. 2020 Aug 5. doi: 10.1001/jamacardio.2020.2981.

Pooling Data From Individual Clinical Trials in the COVID-19 Era. Petkova E, Antman EM, Troxel AB. JAMA. 2020 Jul 22. doi: 10.1001/jama.2020.13042.

Multimodality Imaging in Evaluation of Cardiovascular complications in Patients with COVID-19. Rudski L, Januzzi JL, Rigolin VH, Bohula EA, Blankstein R, Patel AR, Bucciarelli-Ducci C, Vorovich E, Mukherjee M, Rao SV, Beanlands R, Villines TC, Di Carli MF. J Am Coll Cardiol. 2020 Jul 20:S0735-1097(20)36039-3. doi: 10.1016/j.jacc.2020.06.080.

Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.  Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL 3rd, Cange AL, Sabatine MS, O’Donoghue ML.  J Thromb Thrombolysis. 2020 Jul 18. doi: 10.1007/s11239-020-02221-5.

Dapagliflozin and Diuretic Use in Patients with Heart Failure and Reduced Ejection Fraction in DAPA-HF.  Jackson AM, Dewan P, Anand IS, Bělohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, Demets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O’Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJV. Circulation. 2020 Jul 16. doi: 10.1161/CIRCULATIONAHA.120.047077.

Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?  Bergmark BA.  J Am Heart Assoc. 2020 Jul 14:e017888. doi: 10.1161/JAHA.120.017888.

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. Solomon SD, Jhund PS, Claggett BL, Dewan P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJV. JACC Heart Fail. 2020 Jul 5. pii: S2213-1779(20)30254-7.

Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Gilotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. JACC Heart Fail. 2020 Jun 10. pii: S2213-1779(20)30272-9. doi: 10.1016/j.jchf.2020.05.005.

Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers. Gencer B, Giugliano RP. Clin Cardiol. 2020 Jun 29. doi: 10.1002/clc.23410.

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial. Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack CV, Wiviott SD, Rao SV, Jukema JW, Erglis A, Moccetti T, Elbez Y, Steg PG. Int J Cardiol. 2020 Jun 23. pii: S0167-5273(20)33398-2.

The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. O’Donoghue ML, Murphy SA, Sabatine MS. Circulation. 2020 Jun 19. doi: 10.1161/CIRCULATIONAHA.120.046251.

The American Heart Association COVID-19 CVD Registry powered by Get With The Guidelines®. Alger HM, Rutan C, Williams Iv JH, Walchok JG, Bolles M, Hall JL, Bradley SM, Elkind MSV, Rodriguez F, Wang TY, Morrow DA, Das SR, de Lemos JA. Circ Cardiovasc Qual Outcomes. 2020 Jun 17. doi: 10.1161/CIRCOUTCOMES.120.006967.

Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Bělohlávek J, Chopra VK, Dukát A, Kitakaze M, Merkely B, O’Meara E, Schou M, Vinh PN, McMurray JJV; DAPA-HF Investigators and Committees. Eur J Heart Fail. 2020 Jun 15. doi: 10.1002/ejhf.1867.

Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. Dietz N, Ruff C, Giugliano RP, Mercuri MF, Antman EM. Int J Cardiol. 2020 Mar 21. pii: S0167-5273(19)33781-7. doi: 10.1016/j.ijcard.2020.03.055.

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Anker SD, Butler J, Khan MS, Abraham WT, Bauersachs J, Bocchi E, Bozkurt B, Braunwald E, Chopra VK, Cleland JG, Ezekowitz J, Filippatos G, Friede T, Hernandez AF, Lam CSP, Lindenfeld J, McMurray JJV, Mehra M, Metra M, Packer M, Pieske B, Pocock SJ, Ponikowski P, Rosano GMC, Teerlink JR, Tsutsui H, Van Veldhuisen DJ, Verma S, Voors AA, Wittes J, Zannad F, Zhang J, Seferovic P, Coats AJS. Eur Heart J. 2020 Jun 4. pii: ehaa461. doi: 10.1093/eurheartj/ehaa461.

A current review of COVID-19 for the cardiovascular specialist. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. Am Heart J. 2020 May 3;226:29-44. doi: 10.1016/j.ahj.2020.04.025.

Left ventricle unloading strategies in ECMO: A single-center experience. Piechura LM, Coppolino A, Mody GN, Rinewalt DE, Keshk M, Ogawa M, Seethala R, Bohula EA, Morrow DA, Singh SK, Mallidi HR, Keller SP. J Card Surg. 2020 Jun 2. doi: 10.1111/jocs.14644.

Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Napp LC, Cammann VL, Jaguszewski M, Szawan KA, Wischnewsky M, Gili S, Knorr M, Heiner S, Citro R, Bossone E, D’Ascenzo F, Neuhaus M, Franke J, Sorici-Barb I, Noutsias M, Burgdorf C, Koenig W, Kherad B, Sarcon A, Rajan L, Michels G, Pfister R, Cuneo A, Jacobshagen C, Karakas M, Pott A, Meyer P, Arroja JD, Banning A, Cuculi F, Kobza R, Fischer TA, Vasankari T, Airaksinen KEJ, Hauck C, Paolini C, Bilato C, Imori Y, Kato K, Kobayashi Y, Opolski G, Budnik M, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Dichtl W, Chan C, Bridgman P, Beug D, Delmas C, Lairez O, El-Battrawy I, Akin I, Gilyarova E, Shilova A, Gilyarov M, Horowitz JD, Polednikova K, Tousek P, Widimský P, Winchester DE, Galuszka J, Ukena C, Poglajen G, Carrilho-Ferreira P, Di Mario C, Prasad A, Rihal CS, Schulze PC, Bianco M, Crea F, Borggrefe M, Maier LS, Pinto FJ, Braun-Dullaeus RC, Rottbauer W, Katus HA, Hasenfuß G, Tschöpe C, Pieske BM, Thiele H, Schunkert H, Böhm M, Felix SB, Münzel T, Bax JJ, Bauersachs J, Braunwald E, Lüscher TF, Ruschitzka F, Ghadri JR, Templin C. Eur Heart J. 2020 Jun 2. pii: ehaa210. doi: 10.1093/eurheartj/ehaa210.

MRI-EEG correlation for outcome prediction in postanoxic myoclonus: A multicenter study. Beuchat I, Sivaraju A, Amorim E, Gilmore EJ, Dunet V, Rossetti AO, Westover MB, Hsu L, Scirica BM, Silva D, Tang K, Lee JW. Neurology. 2020 Jun 1. pii: 10.1212/WNL.0000000000009610. doi: 10.1212/WNL.0000000000009610.

Reversal Agents: What We Have and What We Can Expect. Ruff CT. J Innov Card Rhythm Manag. 2018 Apr 15;9(4):3108-3114. doi: 10.19102/icrm.2018.090403. eCollection 2018 Apr. Review.

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. JAMA Cardiol. 2020 May 20. doi: 10.1001/jamacardio.2020.0882.

Non-Vitamin K Antagonist Oral Anticoagulant for Atrial Fibrillation in Obese Patients. Wang SY, Giugliano RP. Am J Cardiol. 2020 Apr 23. pii: S0002-9149(20)30384-2. doi: 10.1016/j.amjcard.2020.04.016. [Epub ahead of print] Review.

HRS white paper on atrial fibrillation centers of excellence: Rationale, considerations, and goals. Piccini JP Sr, Allred J, Bunch TJ, Deering TF, Di Biase L, Hussein AA, Lewis WR, Mittal S, Natale A, Osorio J, Packer DL, Ruff C, Russo AM, Sanders P, Seiler A, Slotwiner D, Hills MT, Turakhia MP, Van Gelder IC, Varosy PD, Verma A, Volgman AS, Wood KA, Deneke T. Heart Rhythm. 2020 May 3. pii: S1547-5271(20)30407-0. doi: 10.1016/j.hrthm.2020.04.033.

Cognition After Lowering LDL-Cholesterol With Evolocumab. Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pedersen TR, Keech AC, Ott BR, Sabatine MS, Giugliano RP; FOURIER Investigators. J Am Coll Cardiol. 2020 May 12;75(18):2283-2293. doi: 10.1016/j.jacc.2020.03.039.

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. J Am Heart Assoc. 2020 May 5:e015331. doi: 10.1161/JAHA.119.015331.

Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. Barkoudah E, Piazza G, Hecht TEH, Grant P, Deitelzweig S, Fang MC, Fanikos J, Kao CK, Barnes GD, Chen T, Ramishvili T, Schnipper JL, Goldstein JN, Ruff CT, Kaatz S, Schwartz A, Connors JM, Goldhaber SZ. Am J Med. 2020 May;133 Suppl 1:1-27. doi: 10.1016/j.amjmed.2019.12.001.

Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS. JAMA Cardiol. 2020 Apr 29. doi: 10.1001/jamacardio.2020.0764.

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. Bergmark BA, O’Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceška R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS. JAMA Cardiol. 2020 Apr 29. doi: 10.1001/jamacardio.2020.0728.

No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.  Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin L.  JACC Cardiovasc Interv. 2020 Apr 27;13(8):1012-1014. doi: 10.1016/j.jcin.2020.02.009.

Incidence, predictors and prognosis of respiratory support in non-ST segment elevation myocardial infarction.  Metkus T, Miller PE, Alviar CL, Jentzer JC, van Diepen S, Katz JN, Morrow DA, Schulman S, Eid S.  Eur Heart J Acute Cardiovasc Care. 2020 Apr 23:2048872620919947. doi: 10.1177/2048872620919947.

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.  Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, Murphy SA, Wasserman SM, Honarpour N, Wang H, Lira Pineda A, Sabatine MS; FOURIER Investigators.  Stroke. 2020 Apr 21:STROKEAHA119027759. doi: 10.1161/STROKEAHA.119.027759.

Admission diagnosis and mortality risk prediction in a contemporary cardiac intensive care unit population. Jentzer JC, van Diepen S, Murphree DH, Ismail AS, Keegan MT, Morrow DA, Barsness GW, Anavekar NS. Am Heart J. 2020 Feb 28;224:57-64. doi: 10.1016/j.ahj.2020.02.018.

Disruptive Modifications to Cardiac Critical Care Delivery During the Covid-19 Pandemic: An International Perspective. Katz JN, Sinha SS, Alviar CL, Dudzinski DM, Gage A, Brusca SB, Flanagan MC, Welch T, Geller BJ, Miller PE, Leonardi S, Bohula EA, Price S, Chaudhry SP, Metkus TS, O’Brien CG, Sionis A, Barnett CF, Jentzer JC, Solomon MA, Morrow DA, van Diepen S. J Am Coll Cardiol. 2020 Apr 14. pii: S0735-1097(20)35002-6. doi: 10.1016/j.jacc.2020.04.029.

Use of Temporary Mechanical Circulatory Support for Management of Cardiogenic Shock Before and After the United Network for Organ Sharing Donor Heart Allocation System Changes. Varshney AS, Berg DD, Katz JN, Baird-Zars VM, Bohula EA, Carnicelli AP, Chaudhry SP, Guo J, Lawler PR, Nativi-Nicolau J, Sinha SS, Teuteberg JJ, van Diepen S, Morrow DA; Critical Care Cardiology Trials Network Investigators. JAMA Cardiol. 2020 Apr 15. doi: 10.1001/jamacardio.2020.0692.

COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies. Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. JACC Basic Transl Sci. 2020 Apr 10. doi: 10.1016/j.jacbts.2020.04.002.

Understanding the Sex Paradox After Percutaneous Coronary Intervention: Leveling the Playing Field. O’Donoghue ML, Sarma AA. J Am Coll Cardiol. 2020 Apr 14;75(14):1641-1643. doi: 10.1016/j.jacc.2020.02.048.

The Promise of Mobile Health in Managing Atrial Fibrillation. Ruff CT. J Am Coll Cardiol. 2020 Apr 7;75(13):1535-1537. doi: 10.1016/j.jacc.2020.02.039.

Safety of dapagliflozin in a broad population of patients with type 2 diabetes – analyses from the DECLARE – TIMI 58 study. Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LA. Diabetes Obes Metab. 2020 Apr 2. doi: 10.1111/dom.14041.

Managing Stable Ischemic Heart Disease. Antman EM, Braunwald E. N Engl J Med. 2020 Mar 30. doi: 10.1056/NEJMe2000239. PMID: 32227752

The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O’Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS. Circulation. 2020 Mar 29. doi: 10.1161/CIRCULATIONAHA.120.046397.

Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Vaduganathan M, Singh A, Sharma A, Januzzi JL Jr, Scirica BM, Butler J, Zannad F, McGuire DK, Cannon CP, Bhatt DL. Am J Cardiol. 2020 Mar 4. pii: S0002-9149(20)30175-2. doi: 10.1016/j.amjcard.2020.01.053.

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, Katova T, Ljungman CEA, O’Meara E, Petrie MC, Schou M, Verma S, Vinh PN, Solomon SD, McMurray JJV. Eur Heart J. 2020 Mar 28. pii: ehaa183. doi: 10.1093/eurheartj/ehaa183.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.1906.

Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SD. J Am Coll Cardiol. 2020 Mar 17;75(10):1095-1106. doi: 10.1016/j.jacc.2019.12.067.

Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020. Menown IBA, Giugliano R, Zeymer U. Cardiol Ther. 2020 Mar 6. doi: 10.1007/s40119-020-00166-7.

Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial.
Bajaj HS, Raz I, Mosenzon O, Murphy SA, Rozenberg A, Yanuv I, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Sabatine MS, Wiviott SD, Cahn A. Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011.

Percutaneous right ventricular assist device-supported ventricular tachycardia ablation in a patient with severe right ventricular dysfunction. Aguilar M, Tsao AL, Croce KJ, Sauer W, Morrow DA, Tedrow UB. HeartRhythm Case Rep. 2019 Nov 4;6(2):72-76. doi: 10.1016/j.hrcr.2019.10.019. eCollection 2020 Feb.

Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement. Bandyopadhyay D, Chakraborty S, Amgai B, Kapadia SR, Braunwald E, Naidu SS, Kalra A.JAMA Netw Open. 2020 Feb 5;3(2):e1921669. doi: 10.1001/jamanetworkopen.2019.21669.

2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee. Writing Committee Members, Yancy CW, Drazner MH, Coffin ST, Cornwell W 3rd, Desai S, Erwin JP 3rd, Ginwalla M, Harshaw-Ellis KS, Horwich T, Kittleson M, Lala A, Lewsey SC, Marine JE, Martin CM, Meehan K, Morrow DA, Schlendorf K, Smith JW, Stevens GR. J Am Coll Cardiol. 2020 Feb 14. pii: S0735-1097(19)37741-1. doi: 10.1016/j.jacc.2019.09.030.

Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. Sun MT, Huang S, Wiviott SD, Antman EM, Roe MT, Ohman EM, Neely M, Wallentin L, Wong CX. Am J Cardiol. 2020 Jan 29. pii: S0002-9149(20)30053-9. doi: 10.1016/j.amjcard.2020.01.012.

Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Nanna MG, Navar AM, Giugliano RP, White JA, Lokhnygina Y, Mitchel YB, Musliner TA, Cannon CP, Blazing MA. J Am Coll Cardiol. 2020 Feb 25;75(7):835-837. doi: 10.1016/j.jacc.2019.12.022.

Ejection fraction versus B-type natriuretic peptide for revascularization strategy in left main disease: two sides of the same coin or a wooden nickel? Furtado RHM, Bergmark B. Eur J Heart Fail. 2020 Feb 11. doi: 10.1002/ejhf.1717.

Positive Pressure Ventilation in Cardiogenic Shock: Review of the Evidence and Practical Advice for Patients With Mechanical Circulatory Support. Alviar CL, Rico-Mesa JS, Morrow DA, Thiele H, Miller PE, Maselli DJ, van Diepen S. Can J Cardiol. 2020 Feb;36(2):300-312. doi: 10.1016/j.cjca.2019.11.038. Epub 2019 Dec 12. Review.

Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Plitt A, Ruff CT, Goudev A, Morais J, Ostojic MC, Grosso MA, Lanz HJ, Park JG, Antman EM, Braunwald E, Giugliano RP. Int J Cardiol. 2020 Jan 30. pii: S0167-5273(19)35229-5. doi: 10.1016/j.ijcard.2020.01.009.

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O’Donoghue ML. Eur J Prev Cardiol. 2020 Feb 4:2047487320902750. doi: 10.1177/2047487320902750.

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Furtado RHM, Giugliano RP. Cardiol Ther. 2020 Feb 5. doi: 10.1007/s40119-020-00163-w. Review.

Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Zelniker TA, Braunwald E. J Am Coll Cardiol. 2020 Feb 4;75(4):435-447. doi: 10.1016/j.jacc.2019.11.036. Review.

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. Zelniker TA, Braunwald E. J Am Coll Cardiol. 2020 Feb 4;75(4):422-434. doi: 10.1016/j.jacc.2019.11.031. Review.

Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial. Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Vasc Med. 2020 Jan 30:1358863X19892690. doi: 10.1177/1358863X19892690.

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott SD, McMurray JJV, Granger CB. Circulation. 2020 Jan 29. doi: 10.1161/CIRCULATIONAHA.119.041022.

Response by Bergmark et al to Letter Regarding Article, “Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial”.  Bergmark BA, Bhatt DL, McGuire DK, Scirica BM. Circulation. 2020 Jan 28;141(4):e57-e58. doi: 10.1161/CIRCULATIONAHA.119.044819. Epub 2020 Jan 27.

Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial. Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183.

Incidence, underlying conditions, and outcomes of patients receiving acute renal replacement therapies in tertiary cardiac intensive care units: An analysis from the Critical Care Cardiology Trials Network Registry. van Diepen S, Tymchak W, Bohula EA, Park JG, Daniels LB, Phreaner N, Barnett CF, Kenigsberg BB, DeFilippis A, Singam NS, Barsness GW, Jentzer JC, Ternus B, Morrow DA, Katz JN; Critical Care Cardiology Trials Network Investigators. Am Heart J. 2020 Jan 15;222:8-14. doi: 10.1016/j.ahj.2020.01.005.

The Fourth Universal Definition of Myocardial Infarction and the Emerging Importance of Myocardial Injury. Morrow DA. Circulation. 2020 Jan 21;141(3):172-175. doi: 10.1161/CIRCULATIONAHA.119.044125. Epub 2020 Jan 20.

American Heart Association Vascular Disease Strategically Focused Research Network. Barnett JV1, Beckman JA, Bonaca MP, Carnethon MR, Cassis LA, Creager MA, Daugherty A, Feinberg MW, Freiberg MS, Goodney PP, Greenland P, Leeuwenburgh C, LeMaire SA, McDermott MM, Sabatine MS, Shen YH, Wasserman DH, Webb NR, Wells QS. Arterioscler Thromb Vasc Biol. 2020 Jan 23:ATVBAHA120313967. doi: 10.1161/ATVBAHA.120.313967.

Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. J Am Coll Cardiol. 2020 Jan 28;75(3):289-300. doi: 10.1016/j.jacc.2019.11.035.

Atrial Failure as a Clinical Entity: JACC Review Topic of the Week. Bisbal F, Baranchuk A, Braunwald E, Bayés de Luna A, Bayés-Genís A. J Am Coll Cardiol. 2020 Jan 21;75(2):222-232. doi: 10.1016/j.jacc.2019.11.013. Review.

Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Shah S et al. Nat Commun. 2020 Jan 9;11(1):163. doi: 10.1038/s41467-019-13690-5.

Notable TIMI publications from 2019:

Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial). Alkhalfan F, Nafee T, Yee MK, Chi G, Kalayci A, Plotnikov A, Braunwald E, Gibson CM. Am J Cardiol. 2019 Dec 9. pii: S0002-9149(19)31363-3. doi: 10.1016/j.amjcard.2019.12.007.

Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O’Donoghue ML. J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022. doi: 10.1016/j.jacc.2019.09.065. Epub 2019 Dec 9.

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I. Diabetes Care. 2019 Dec 16. pii: dc191476. doi: 10.2337/dc19-1476.

Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O’Connor CM. Circulation. 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16.

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ; PIONEER-HF Investigators.  JAMA Cardiol. 2019 Dec 11. doi: 10.1001/jamacardio.2019.4665.

Respiratory support in acute heart failure with preserved vs reduced ejection fraction. Metkus TS, Stephens RS, Schulman S, Hsu S, Morrow DA, Eid SM.  Clin Cardiol. 2019 Dec 11. doi: 10.1002/clc.23317.

Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. Skranes JB, Claggett BL, Myhre PL, Lyngbakken MN, Solomon SD, Sabatine MS, Pfeffer MA, Omland T.  Circulation. 2019 Dec 10;140(24):2044-2046. doi: 10.1161/CIRCULATIONAHA.119.041991. Epub 2019 Dec 9.

Veno-Arterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock: An Introduction for the Busy Clinician. Eckman PM, Katz JN, El Banayosy A, Bohula EA, Sun B, van Diepen S.  Circulation. 2019 Dec 10;140(24):2019-2037. doi: 10.1161/CIRCULATIONAHA.119.034512. Epub 2019 Dec 9.

Baseline Characteristics of the VANISH Cohort. Axelsson Raja A, Shi L, Day SM, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall EK, Becker J, Jefferies JL, Patel AR, Choudhury L, Murphy AM, Canter C, Bach R, Taylor M, Mestroni L, Wheeler MT, Benson L, Owens AT, Rossano J, Lin KY, Pahl E, Pereira AC, Bundgaard H, Lewis GD, Vargas JD, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E, Ho CY.  Circ Heart Fail. 2019 Dec;12(12):e006231. doi: 10.1161/CIRCHEARTFAILURE.119.006231. Epub 2019 Dec 9.

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP.  Eur Heart J. 2019 Dec 7. pii: ehz821. doi: 10.1093/eurheartj/ehz821. [Epub ahead of print].

Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Inciardi RM, Giugliano RP, Claggett B, Gupta DK, Chandra A, Ruff CT, Antman EM, Mercuri MF, Grosso MA, Braunwald E, Solomon SD; ENGAGE AF-TIMI 48 Investigators. Eur J Heart Fail. 2019 Nov 27. doi: 10.1002/ejhf.1606. [Epub ahead of print].

Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial. Kosiborod MN, Jhund P, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køeber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJV. Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044138.

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, Demets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJV. Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044133.

Rationale and design of a navigator-driven remote optimization of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. Blood AJ, Fischer CM, Fera LE, MacLean TE, Smith KV, Dunning JR, Bosque-Hamilton JW, Aronson SJ, Gaziano TA, MacRae CA, Matta LS, Mercurio-Pinto AA, Murphy SN, Scirica BM, Wagholikar K, Desai AS. Clin Cardiol. 2019 Nov 14. doi: 10.1002/clc.23291.

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.043805.

REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States. Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif JC, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM; REDUCE-IT Investigators. Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044440.

Clinical Practice Patterns in Temporary Mechanical Circulatory Support for Shock in the Critical Care Cardiology Trials Network (CCCTN) Registry. Berg DD, Barnett CF, Kenigsberg BB, Papolos A, Alviar CL, Baird-Zars VM, Barsness GW, Bohula EA, Brennan J, Burke JA, Carnicelli AP, Chaudhry SP, Cremer PC, Daniels LB, DeFilippis AP, Gerber DA, Granger CB, Hollenberg S, Horowitz JM, Gladden JD, Katz JN, Keeley EC, Keller N, Kontos MC, Lawler PR, Menon V, Metkus TS, Miller PE, Nativi-Nicolau J, Newby LK, Park JG, Phreaner N, Roswell RO, Schulman SP, Sinha SS, Snell RJ, Solomon MA, Teuteberg JJ, Tymchak W, van Diepen S, Morrow DA. Circ Heart Fail. 2019 Nov;12(11):e006635. doi: 10.1161/CIRCHEARTFAILURE.119.006635. Epub 2019 Nov 11.

Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. Samsky M, Krucoff M, Althouse AD, Abraham WT, Adamson P, Aguel F, Bilazarian S, Dangas GD, Gilchrist IC, Henry TD, Hochman JS, Kapur NK, Laschinger J, Masters RG, Michelson E, Morrow DA, Morrow V, Ohman EM, Pina I, Proudfoot AG, Rogers J, Sapirstein J, Senatore F, Stockbridge N, Thiele H, Truesdell AG, Waksman R, Rao S. Am Heart J. 2019 Nov 7;219:1-8. doi: 10.1016/j.ahj.2019.10.006.

Reply: Anticoagulants in Atrial Fibrillation and Liver Disease. Qamar A, Antman EM, Giugliano RP. J Am Coll Cardiol. 2019 Nov 12;74(19):2436-2437. doi: 10.1016/j.jacc.2019.09.010. No abstract available.

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Bhatt DL, Verma S, Braunwald E. Cell Metab. 2019 Nov 5;30(5):847-849. doi: 10.1016/j.cmet.2019.10.008.

Efficacy and Safety of Edoxaban Compared to Warfarin According to the Burden of Diseases in Patients with Atrial Fibrillation: Insights from the ENGAGE AF-TIMI 48. Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, Duris T, Juul-Möller S, Voitk J, Trevisan M, Nordio F, Antman EM, Giugliano RP. Eur Heart J Cardiovasc Pharmacother. 2019 Nov 5. pii: pvz061. doi: 10.1093/ehjcvp/pvz061.

Diastolic Dysfunction in Patients with Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results from the CHART Study. Butler J, Greene SJ, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E.J Card Fail. 2019 Nov 1. pii: S1071-9164(19)30584-6. doi: 10.1016/j.cardfail.2019.10.011.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. McClung MR, O’Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. Lancet Diabetes Endocrinol. 2019 Oct 29. pii: S2213-8587(19)30346-8. doi: 10.1016/S2213-8587(19)30346-8.

Response by Kato et al to Letter Regarding Article, “Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus”. Kato ET, Sabatine MS, Wiviott SD. Circulation. 2019 Oct 29;140(18):e740-e741. doi:10.1161/CIRCULATIONAHA.119.042848.

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJ. J Am Coll Cardiol. 2019 Oct 29;74(17):2132-2146. doi: 10.1016/j.jacc.2019.08.1024.

Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2°P-TIMI 50 Trial. Xu H, Bonaca MP, Goodrich E, Scirica BM, Morrow DA. Eur Heart J Acute Cardiovasc Care. 2019 Oct 23:2048872619883354. doi: 10.1177/2048872619883354.